POPULARITY
10 episodes with Ottawa Hospital Research Institute
4 episodes with Ottawa Hospital Research Institute
2 episodes with Ottawa Hospital Research Institute
3 episodes with Ottawa Hospital Research Institute
2 episodes with Ottawa Hospital Research Institute
2 episodes with Ottawa Hospital Research Institute
16 episodes with Ottawa Hospital Research Institute
2 episodes with Ottawa Hospital Research Institute
2 episodes with Ottawa Hospital Research Institute
How can we improve outcomes for cancer patients undergoing surgery? With Immunotherapy! In this episode we discuss perioperative immunotherapy with Dr. Rebecca Auer, a Surgeon-Scientist and the CEO & Scientific Director at the Ottawa Hospital Research Institute. She discusses how her background in surgery and interest in research led her to explore how we can enhance the immune system after surgical removal of cancers to prevent relapse.More information about the clinical trial using a blood thinner to boost the immune response after colon cancer removal: News articleMedical Journal publication--Interested in learning more about immunotherapy? Check out our other episodes and give us a follow on instagram @wthisimmunotherapy and twitter @WTHisImmunoT! And check out our website wthisimmunotherapy.com. Or feel free to reach out to us at wthisimmunotherapy@gmail.com if you have any questions or any ideas for episodes!--Creators & Producers: Gillian Savage, Grace Bernard, and Dr. Pauline Loos Podcast Logo is designed by Mia Portelance Music is by Lara Antebi (https://laraantebi.bandcamp.com/)
Lia Morton from the University of Ottawa interviews Dr. Marisa Azad. Dr. Azad is a physician-scientist at the Ottawa Hospital Research Institute and an Assistant Professor of medicine in the division of infectious diseases at the University of Ottawa. In this episode, Dr. Azad shares her insight and expertise on implant-associated infections (IAIs), notably the challenges of detecting and diagnosing IAIs and emerging diagnostic methods.Learn more: https://www.ohri.ca/newsroom/story/view/1543?l=en 0:00 | BEaTS and host introduction.0:38 | Introduction to Implant-Associated Infections (IAIs)1:40 | Introduction to Dr.Azad.2:11 | Why is IAI diagnosis so difficult, and what makes it particularly challenging?3:39 | Implant types that are notably hard to detect.4:29 | How do biofilms contribute to the formation of IAIs, and what makes them dangerous?7:41 | Limitations associated with microbiological analyses.11:09 |Future work and new approaches considered to identify IAIs.12:59 |The diagnostic methods currently being used in the clinic14:26 | Farewells and closure.Soundtrack by The Underground Drive. Song Titled: BEaTS. All rights reserved.https://music.apple.com/ca/artist/the-underground-drive/1571062779https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmRLia Morton (Show Host, Content Generation), Julianne Morin (Production, Content Generation), Amal Assebbane (Script, Content Generation), Adjia Seynabou Sy Gueye (Post-Production, Content Generation)
Join Kahliana Nguyen and Khaled Najjar, Translational and Molecular Medicine students, as they speak with Dr. Baptiste Lacoste, a neuroscience researcher at the Ottawa Hospital Research Institute whose recent work focuses on the critical role of the brain's vascular system in development. The episode explores a new perspective on autism spectrum disorders (ASD) and how problems with the brain's blood vessels in early development may contribute to challenges seen in autism. Dr. Lacoste goes into depth on how these blood vessels play a role in brain growth, energy use, and behavior. By studying these interactions alongside neural and genetic factors, his research opens new avenues in how we understand autism and find better ways to address ASD. Whether you're a researcher, student, or simply curious, this episode offers an exciting new lens to the field. Learn more: Dr Baptiste Lacoste Dr Baptiste Lacoste | Faculté de médecine https://bsky.app/profile/blacoste.bsky.socialhttps://www.ohri.ca/profile/lacostelab0:02 | BEaTS and host introduction.0:22 | Introduction to Dr. Lacoste1:10 | Why did Dr. Lacoste choose to focus on the vascular system specifically?3:05 | The Neurovascular unit (NVU) and its importance in Dr. Lacoste's research on ASD5:15 | The use of mice with a 16p11.2 deletion mutation to study ASD8:43 | The novel findings were seen in Dr. Lactoste's lab study on ASD10:51 | Treatment Strategies when it comes to ASD12:03 | Limitations & Challenges Dr. Lacoste's lab faced and still faces while studying ASD13:50 | Wrapping up the episodeScience and Innovation by Vicate. All rights reserved. Listen more:https://www.jamendo.com/album/578641/science-and-innovationVicate | Jamendo Music | Free music downloadsKahliana Nguyen (Voice) & Khaled Najjar (Producer & Editor)
Matteus McCulloch from the University of Ottawa interviews Dr. Michele Ardolino, a senior scientist in cancer research at the Ottawa Hospital Research Institute and an Assistant Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. In this episode, Dr. Ardolino discusses a recent paper published by his lab about PD-L1 and its inhibition of the Type I IFN pathway during oncolytic virus infection, how the research came about, and the relevance of the work to advance cancer treatment. Learn more about Dr. Ardolino and the work of the Ardolino Lab: https://www.uottawa.ca/faculty-medicine/dr-michele-ardolino https://ardolinolab.ca/0:00 | Introduction to PD-L1 and the type I IFN pathway and its relevance to recent research by Hodgins, J.J. et al. 1:40 | BEaTS, host, and guest introduction2:18 | What inspired the Ardolino Lab's exploration of PD-L1 and the type I IFN pathway?5:01 | What setbacks were encountered over the course of this study?6:35 | What is the mechanism of action for PD-L1 antibodies and oncolytic viruses in cancer therapy?8:17 | Clinical applications of PD-L1 antibodies and oncolytic viruses for cancer therapy9:50 | Impactful moments during the research process10:57 | Next steps in PD-L1 research12:02 | Advice for students entering research13:30 | End creditsThis podcast features the following songs: "Hidden Realm" by I.V.Lab, available under a Creative Commons Attribution-NonCommercial license.Listen here: https://archive.org/details/ffs62"600 light years" by Macroform, available under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 license.Listen here: https://archive.org/details/Macroform2011Matteus McCulloch (Podcast Host), Serena Bezanson (Script Writer), Sara Ladha (Audio post-production), Mattheuren Aucoin (Producer).
In this episode, your host, Emily Schraeder, speaks to Dr. Christian Vaillancourt, Full Professor with the Department of Emergency Medicine, University of Ottawa, and Senior Scientist at the Ottawa Hospital Research Institute. His research looks at pre-hospital care, specifically improving care and survival for cardiac arrest and trauma victims. He implemented a multi-phase protocol to allow nurses to use automated external defibrillators (AEDs) during in-hospital cardiac arrest and studied its impact on survival. His research has a major impact on the care and treatment of cardiac arrest victims in our hospitals. We also hear from Julie Considine, Deakin Distinguished Professor, who is Chair of Nursing at Eastern Health and Director of the Centre for Quality and Patient Safety Research, who gives her point of view on this protocol.Learn more: https://www.ohri.ca/profile/cvaillancourt1:23 | What is an AED? Why is an AED important? 3:16 | Why is the 3-minute time frame so important? Why can it take up to 12 minutes for the first shock to occur?5:28 | Why are nurses not allowed to use AED in hospitals?7:47 | What were the study's challenges or different opinions and views?10:08 | From a nursing perspective, what are some strengths and weaknesses of this protocol?12:07 | How do you expect these protocols to be implemented in the long term?13:49 | Is there anything that you, Dr. Vaillancourt, want the listeners to know about AED use?Soundtrack by The Underground Drive. All rights reserved. Listen more:https://music.apple.com/ca/artist/the-underground-drive/1571062779 https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmR Producer: Stephanie KhouryShow host: Emily SchraederWriter editor: Hannah Verge and Elizabeth ThibeaultAudio master: Stephanie Khoury and Emily Schraeder
Batoul Jomaa from the University of Ottawa interviews Dr. Marisa Azad and Dr. Robin Patel on behalf of her team for the TMM4950 Science Communication course about improving the diagnostic methods for periprosthetic joint infections (PJIs). Dr. Azad is a senior scientist and physician of infectious diseases at the Ottawa Hospital Research Institute and a cross-appointed assistant professor at the University of Ottawa. Dr. Azad's research focuses on exploring PJI to develop more efficient diagnostic methods. Dr. Robin Patel is a director of the Infectious Disease Research Laboratory and a clinician at the Mayo Clinic. In this episode, Dr. Azad and Dr. Patel present their findings from their research on new diagnostic methods for PJI, how diagnostic methods can improve, and important considerations regarding PJI. Learn more: https://www.uottawa.ca/faculty-medicine/dr-marisa-azad0:05 | Introduction to podcast1:15 | Introduction to Dr. Azad1:44 | Why is diagnosing PJIs so difficult and what are the current standard treatments?4:20 | What is the BioFire Joint Infection (JI) panel and how does it work?5:20 | What are the plans to improve the accuracy of the BioFire Joint Infection (JI) panel?7:23 | How will antimicrobial resistance affect the prevalence of PJIs and diagnostic strategies?9:25 | Introduction to Dr. Robin Patel10:00 | Are PJIs typically caused by one or multiple microbes?11:58 | Will biomaterials reduce the risk of PJIs or introduce new problems?14:32 | Closing remarksCredits for music: Soundtracks by the Underground Drive. All rights reserved. Listen more https://music.apple.com/ca/artist/the-underground-drive/1571062779https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmRBatoul Jomaa (Voice), Tony Lin (Post-Production), Abha Ranjitkar (Content Generation), Sam Khanlou (Producer)
Giselle Joseph of the University of Ottawa interviews Dr. Deborah M. Siegal of the Ottawa Hospital Research Institute about how a simple change in blood collection practices in ICUs could significantly improve patient care. Dr. Siegal is a hematologist, clinician-scientist at the Ottawa Hospital Research Institute, and Associate Professor of Medicine at the School of Epidemiology and Public Health at the University of Ottawa.Learn more: https://www.ohri.ca/profile/dsiegal0:06 | Introduction0:56 | Motivation behind using small-volume tubes in ICUs3:15 | Study design and challenges 6:19 | COVID-19 and adaptations to the study 8:46 | Limitations and interpretation of results11:23 | Next steps Soundtrack by The Underground Drive. All rights reserved. Listen more:https://music.apple.com/ca/artist/the-underground-drive/1571062779https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmRNatasha Trehan (Producer), Giselle Joseph (Host), Emma Mahoney (Content Writer), Angela Guevara (Post-Production)
Tune in as Polly sits down with Kearstyn Shaw and Dr. David Picketts with BFLS Incorporated. Kearstyn's son was diagnosed with BFLS in 2021. Kearstyn has been a strong advocate for her son and her community since the diagnosis. Dr. David Picketts is a researcher at the Ottawa Hospital Research Institute. His research is focused on understanding the role of epigenetic regulators in brain development and neurodevelopmental disorders (NDDs). Dr. Picketts works closely with Kearstyn to help find a cure and treatments for BFLS. Enjoy!
Dr Deborah Siegal joins us for a discussion on the recent paper, The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-analysis. In this wide-ranging discussion she reviews the results of the sub-analysis and the need for anticoagulant reversal for acute GI bleeding. This discussion provides her perspective on the issue of bleeding with DOACs and the challenges in patient management.Dr. Deborah Siegal MD MSc FRCPC is a clinician-scientist hematologist (thrombosis medicine) at The Ottawa Hospital, Associate Professor of Medicine and School of Epidemiology and Public Health at the University of Ottawa, and Scientist at the Ottawa Hospital Research Institute. Her primary research interest is improving the safety of anticoagulant therapy including optimizing the management of anticoagulant-related bleeding complications, restarting anticoagulants after bleeding, perioperative management of anticoagulants, and antithrombotic therapies for ischemic stroke in patients with cancer. Dr Siegal is a member of the board of directors of Thrombosis Canada. Reference:Siegal DM, Forbes N, Eikelboom J, Beyer-Westendorf J, Cohen AT, Xu L, Connolly SJ, Crowther M. The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis. Circulation. 2024 Apr 16;149(16):1315-8.https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.123.066933Follow us on Twitter:@ThrombosisCan@debsiegalSupport the Show.https://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
The internet is full of examples of failed innovations... The Segway, The PalmPilot, MySpace... tech that started revolutions, but failed to scale. This phenomenon is not specific to Silicon Valley. In fact, it is very present in healthcare. On this episode of the I'm Pharmacy Podcast, we chat diffusion and implementation. What can innovators learn from failed innovatrions to better navigate the healthcare market? Chatting with industry experts, we will explore in the world of developing interventions, and the emerging excitement of artificial intelligence in healthcare. Featured guests: Dr. Jeremy Grimshaw Senior Scientist at The Ottawa Hospital Research Institute, Professor in the Department of Medicine at the University of Ottawa Dr. Muhammad Mamdani Vice President of Data Science and Advanced Analytics at Unity Health Toronto Director, U of T's Centre for Artificial Intelligence, Education and Research and Medicine Professor (status), Leslie Dan Faculty of Pharmacy
In this episode, Megan Lowe of CFMS Research in Medicine interviews Dr. Shawn Aaron, a distinguished respirologist and senior Scientist at the Ottawa Hospital Research Institute, University of Ottawa. Dr. Aaron shares insights from his journey as a clinician-scientist, offering valuable guidance on navigating the balance between research and clinical practice. He emphasizes the importance of mentorship and imparts key life lessons, highlighting perseverance and persistence as essential qualities for success in research endeavors.
This episode features Dr Fiona Kenney and Koby Anderson, (Ottawa Hospital Research Institute, Ottawa, ON, Canada Bruyère Research Institute, Ottawa, ON, Canada) What is already known about the topic? Previous research demonstrates a high prevalence of severe grief symptoms up to a year post-death of a loved one among those who experienced bereavement during the COVID-19 pandemic. No previous study has assessed changes in the severity of grief more than a year after the death of a loved one during the COVID-19 pandemic. What this paper adds? This prospective cohort follow-up study found the prevalence of severe grief reaction remained high (28.8%) at 12–18 months post- family member death. One-third (33.3%) of family members experienced persistently high or worsening grief symptoms at the time of their 12–18-month assessment compared to baseline 6–12-month assessment. Grief severity was associated with endotracheal intubation in the deceased, but not with the cause of death (e.g., COVID vs non-COVID illness) or physical presence/absence of the family member at the bedside in the final 48 h of life. Implications for practice, theory, or policy There is a persistent, elevated risk of severe grief among family members who experience bereavement during the pandemic period, even up to 18 months post-death of the decedent. There is an urgent need for effective and scalable means of addressing severe grief in the wake of the COVID-19 pandemic. Full paper available from: https://journals.sagepub.com/doi/full/10.1177/02692163231223394 If you would like to record a podcast about your published (or accepted) Palliative Medicine paper, please contact Dr Amara Nwosu: a.nwosu@lancaster.ac.uk
Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to unveil an exciting development: a new Master Deployment Agreement with the Ottawa Hospital Research Institute (OHRI). As an academic health research institute located in Ottawa, OHRI serves as the research arm of The Ottawa Hospital and is affiliated with the University of Ottawa. With approximately 2,200 scientists, clinician investigators, students, research fellows, and support staff, OHRI is dedicated to studying a wide array of diseases, conditions, and specialties, with a primary focus on translating discoveries into improved health outcomes. Kaul explained to Proactive that researchers at OHRI will leverage Cloud DX Connected Health products and services to facilitate remote patient monitoring, communication via video and text, schedule and compliance management, and enhanced clinical study efficiencies. By utilizing Cloud DX technology, researchers aim to conduct higher quality clinical studies, streamline subject recruitment processes, and gather more comprehensive data from each participant. Each order for Cloud DX technology will be accompanied by a separate Statement of Work, with plans in motion for projects involving over 1,000 patients. Cloud DX boasts a successful track record of academic partnership, having collaborated with esteemed institutions such as McMaster University, University of New Brunswick, University of Waterloo, and Simon Fraser University. This new agreement with OHRI further solidifies Cloud DX's commitment to advancing healthcare research and innovation, empowering researchers with cutting-edge technology to drive improved patient outcomes and clinical study efficiencies. With this partnership in place, Cloud DX is poised to continue its mission of revolutionizing healthcare delivery through innovative solutions and strategic collaborations with leading academic and research institutions. #proactiveinvestors #clouddxinc #tsxv #cdx #otc #cdxff #medical #remotemonitoring #HealthcareInnovation, #OttawaHospital, #MedicalResearch, #DigitalHealth, #CanadianHealthcare, #ClinicalTrials, #PatientMonitoring, #HealthTech, #MedTech, #VirtualCare, #RemoteMonitoring, #PatientCareTechnology, #HealthcareSolutions, #MedicalTechnology, #HealthcareEfficiency, #InnovativeHealthcare, #HealthcareEvolution, #HealthcarePartnerships, #Telemedicine, #ConnectedCare, #HealthcareTransformation, #FutureOfHealthcare, #PatientOutcome, #HealthcareCollaboration #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
A recent report showed that Canada's national life expectancy dropped for the third year in a row—now sitting at an average of 81.3 years. Why are experts calling this decline a historical change? How does your own life expectancy compare, and how can you make tweaks in your routine to help you increase your lifespan and your healthspan? Here, Dr. Peter Nord is joined by Dr. Doug Manuel, MD, director of the Big Life Lab at the Ottawa Hospital Research Institute and expert in preventive medicine. The two docs explore the implications of a shorter national life expectancy on your life, and the most important things you can do to avoid becoming part of that statistic. Check out the episode webpage for links and more info.
Alongside the many thousands of Cochrane reviews of the effects of health care interventions, is a review of decision aids that might help people make decisions about treatment or screening. This was first published in January 2003 and the fifth update has been published 21 years later. Here's the current lead author, Dawn Stacey from the University of Ottawa and Ottawa Hospital Research Institute in Canada, who's been working on the review for all that time to tell us about the need for the review and its latest findings.
Alongside the many thousands of Cochrane reviews of the effects of health care interventions, is a review of decision aids that might help people make decisions about treatment or screening. This was first published in January 2003 and the fifth update has been published 21 years later. Here's the current lead author, Dawn Stacey from the University of Ottawa and Ottawa Hospital Research Institute in Canada, who's been working on the review for all that time to tell us about the need for the review and its latest findings.
This episode of Beats Radio, hosted by Danyaal Ansari, written by Shay Patel, produced by Hasssan Taleb, and edited by Anas Khoja, features an in-depth discussion with immunology expert Dr. Michele Ardolino from the University of Ottawa and the Ottawa Hospital Research Institute. The conversation centers around the fascinating interplay between the immune system and cancer, with a particular focus on the process of trogocytosis and its role in immune evasion by cancer cells. Dr. Ardolino elaborates on his groundbreaking research into how cancer cells transfer PD-1 to Natural Killer (NK) cells via trogocytosis, effectively inhibiting these critical components of the immune response. This detailed exploration sheds light on the sophisticated mechanisms cancer cells employ to evade immune detection and opens up discussions about potential therapeutic strategies targeting these interactions.https://www.ohri.ca/profile/mardolino/cancer-immunology-lab0:00 - Introduction0:57 - Trogocytosis Explained2:51 - Choosing Trogocytosis for PD-1 Transfer Study5:00 - NK Cells' Functional Variability8:10 - Immune System's Complexity & Beauty10:50 - Rapid Fire Q&A14:27 - Closing RemarksPodcast by Danyaal Ansari (Host), Shay Patel (Writer), Hasssan Taleb (Producer), Anas Khoja (Editor)Music by "Podcast Background Music" https://www.youtube.com/watch?v=cdFqvdekuvI
Félix Labonté, an undergraduate student in the Translational and Molecular Medecine program at the University of Ottawa speaks with Dr. Dylan Burger. Dr. Burger is an associate professor at The University of Ottawa in The Department of Cellular and Molecular Medicine, cross-appointed member in the School of Pharmaceutical Sciences, and an investigator at The Ottawa Hospital Research Institute. Tune into today's podcast to learn more about Dr. Burger's research, published in the Journal of Extracellular Vesicles which demonstrates how extracellular vesicles secreted by the kidneys could potentially be used for targeted therapy advancing our knowledge on diabetic nephropathy and treatments. Learn more: https://www.ohri.ca/profile/dylanburger 0:16 | Introduction1:00 | Dr. Dylan Burger Introduction1:44 | What are extracellular vesicles and what role do they play in healthy cells?2:52 | What is diabetic nephropathy and why is your lab interested in this condition?3:55 | What is the impact of diabetic kidney disease on microparticles released by the podocytes?4:35 | What is the impact of the microparticles released by the podoocytes?5:57 | What would be the next steps for your lab to complete to understand the mechanism of intracellular communication between the podocytes and the proximal tubule epithelial cells?7:16 | Are there any specific medications being tested right now as potential treatments for these types of kidney diseases?8:26 | For extracellular vesicles in general, what's their potential to be used as biomarkers for certain diseases? How could it be used in a clinical setting?10:24 | Closing remarks10:48 | ConclusionSoundtracks by the Underground Drive. All rights reserved. Listen more: https://music.apple.com/ca/artist/the-underground-drive/1571062779https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmR
Fiona Haugen of the University of Ottawa speaks with Dr. Smita Pakhale of the Ottawa Hospital Research Institute about the impact of health inequities on the development of obstructive lung diseases in urban poor populations. Dr. Pakhale is a Senior Scientist, staff respirologist at The Ottawa Hospital, and associate professor at the University of Ottawa who created The Bridge Engagement Center. The Bridge conducts research in partnership with and to improve the well-being of underserved populations in Ottawa, Ontario. Learn more: https://bridgeengagement.ca/00:05 | Introduction01:10 | Overview of Dr. Pakhale's research02:51 | The Bridge Engagement Center03:44 | Tobacco and Ottawa's urban poor population05:51 | Social determinants of health and lung disease07:18 | Building trust with marginalized communities09:15 | Unjustified exclusion of underserved communities in mainstream research 11:22 | Addressing inequities in health and research13:01 | How can we do our part?14:12 | Conclusion and thanksPodcast by Fiona Haugen (host and graphic design), Amandine Courtemanche (writer), Mairead Green (producer), Jade Poirier (audio-producer and writer)Soundtrack by Grand_Project from Pixabay. All rights reserved. Listen more: https://pixabay.com/users/grand_project-19033897/?utm_source=link-attribution&utm_medium=referral&utm_campaign=music&utm_content=177572 https://pixabay.com//?utm_source=link-attribution&utm_medium=referral&utm_campaign=music&utm_content=177572
Small-volume blood collection tubes may decrease red blood cell transfusions in intensive care units without affecting laboratory analysis. JAMA Associate Editor Christopher W. Seymour, MD, MSc, discusses the results and implications of the STRATUS trial with Deborah M. Siegal, MD, MSc, of Ottawa Hospital Research Institute. Related Content: Small-Volume Blood Collection Tubes to Reduce Transfusions in Intensive Care
Spinal Muscular Atrophy (SMA) is a devastating genetic disease that causes muscle weakness and atrophy (shrinking of muscles) in children. There is currently no cure for this disease; however, base editing, a type of gene therapy, provides potential. Dr. Rasthmi Kothary is the Deputy Scientific Director and Senior Scientist at the Ottawa Hospital Research Institute. His lab focuses on understanding the mechanisms that underlie muscle and nervous system integrity. In this episode, Dr. Kothary gives us a greater insight on what SMA is, how it is currently being treated, and his research so far on a new base editing system to potentially cure this disease. Episode produced & hosted by: Nicole Chu Learn more: https://www.ohri.ca/profile/rkothary
This episode of the IASP-PRF Podcast highlights an emerging resource for adults and youths with the lived experience of pain called the Power Over Pain Portal. The Power Over Pain Portal works toward improving access to chronic pain care by providing access to free resources in a “one-stop shop,” including articles, videos, podcasts, courses, workshops, peer support, and even 24/7 one-on-one counseling – offered through Wellness Together Canada. While initiated and designed by a consortium of researchers, clinicians, patient partners, hospitals, and institutions in Canada, the Power Over Pain Portal is freely available worldwide. In this episode, PRF spoke with developers of the Power Over Pain Portal to learn more about its initiation, resources, and plans for the future. Podcast participants include: Lynn Cooper, Director of Research & Education – Canadian Injured Workers Alliance Jennifer Stinson, RN-EC, PhD, CPNP, FAAN, SickKids, Toronto, Canada Yaad Shergill, DC, MSc, The Ottawa Hospital Research Institute, and One Elephant Integrative Health Team Inc., Ontario, Canada Gregory Carbonetti, PhD, IASP Associate Director of Publications (host)
On episode 2 of As PER Usual, a podcast for practical patient engagement, it's all about how patient partners are compensated - if at all! (And no, paying for parking to attend the meeting doesn't count!)Our guests today are the dynamic duo of Grace Fox and Maureen Smith, who teamed up on Grace's recent Master's thesis to explore the current state of patient partner compensation guidance in the literature. In this episode, they discuss how researchers can champion patient partner compensation in their own research practices, and more broadly, within their current academic and clinical institutions.Grace Fox is currently a Strategies for Patient-Oriented Research Assistant at the Ottawa Hospital Research Institute where she helps researchers and patient partners navigate patient engagement in health research. She recently graduated from the Master's of Science in Epidemiology program at the University of Ottawa where she focused her thesis on understanding the current landscape of patient partner compensation. Her thesis included 1) a systematic review to assess reporting of patient partner compensation and current practices, 2) a survey of researchers and institutions to identify challenges and barriers to compensation and 3) a scoping review to capture published guidance and policy around patient partner compensation. Maureen Smith has a long history of collaboration with the healthcare system subsequent to a rare disease diagnosis in childhood. She had the privilege to be a member of Grace's thesis advisory committee as she explored compensation from an institutional and researcher perspective.=-=-=-Visit our Substack for a transcript and links to resources shared by our guests. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit asperusual.substack.com
Cochraneova zbirka sustavnih pregleda o COVIDu-19 obuhvaća dijagnozu i liječenje bolesti, a pregledi se ažuriraju čim novi dokazi postanu dostupni. Među njima je i sustavni pregled o snimanju prsnog koša za dijagnosticiranje zaraze, a njegova četvrta verzija objavljena je u svibnju 2022. Zamolili smo glavnog autora, Sanam Ebrahimzadeh, iz Ottawa Hospital Research Institute u Kanadi, da nam opiše najnovija otkrića. Karmen Vilović, studentica 6. godine medicine na Medicinskom fakultetu Sveučilišta u Splitu i suradnica hrvatskog Cochrane-a, prevela je razgovor i govorit će nam o tome.
Cochraneova zbirka sustavnih pregleda o COVIDu-19 obuhvaća dijagnozu i liječenje bolesti, a pregledi se ažuriraju čim novi dokazi postanu dostupni. Među njima je i sustavni pregled o snimanju prsnog koša za dijagnosticiranje zaraze, a njegova četvrta verzija objavljena je u svibnju 2022. Zamolili smo glavnog autora, Sanam Ebrahimzadeh, iz Ottawa Hospital Research Institute u Kanadi, da nam opiše najnovija otkrića. Karmen Vilović, studentica 6. godine medicine na Medicinskom fakultetu Sveučilišta u Splitu i suradnica hrvatskog Cochrane-a, prevela je razgovor i govorit će nam o tome.
Welcome to the very first episode of As PER Usual, a podcast for practical patient engagement. To start our journey, we have two wonderful guests, Dr. Dawn Richards and Dr. Stuart Nicholls, who - along with several other colleagues - published the "Ottawa model" for patient engagement. They share with the listeners how patient engagement can be embedded in our existing structures, and why it takes more than money to make patient engagement in research move from fiction to fact. Dr. Stuart Nicholls is the Strategy for Patient-Oriented Research (SPOR) Program Facilitator in the Office for Patient Engagement in Research Activities (OPERA) at the Ottawa Hospital Research Institute. In his capacity as SPOR Program facilitator Stuart consults with researchers to provide methodological guidance regarding all aspects of Patient-Oriented Research. With a PhD (Analytical Chemistry) from the University of Alberta, Dr. Dawn Richards has worked in a variety of roles over the past 20 years, however her diagnosis with rheumatoid arthritis over 15 years ago started a journey to combine her passion for science with making the most of her diagnosis. She has contributed to the literature and practice in patient engagement on compensation, authorship, recognizing patients as people with skills and who lead fulfilling lives, and training on patient engagement in research. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit asperusual.substack.com
With Dr. Barbara Vanderhyden, Corinne Boyer Chair in Ovarian Cancer Research at the University of Ottawa. Like many things related to sexual and reproductive health, there's elevated stigma about gynecological cancers. Like many health issues for women, girls, and gender-diverse people, there are serious gaps in knowledge and treatment, too. The gaps are bigger for those who face discrimination based on factors like race, ability, and income. It's ironic that modern biological research is based on cells taken from a woman named Henreitta Lacks in 1951 at Johns Hopkins Hospital. Lacks was a Black woman diagnosed with cervical cancer. Her cells were taken without her consent and cultivated into the HeLa cell line, the most commonly used cell line in scientific research today. Those most marginalized, dealing with the poorest treatment and outcomes and most stigmatized and understudied health issues are the ones we've built our medical practices on. Since May 28, International Day of Action for Women's Health, we've focused on gender and health matters we may know bits and pieces of but probably need to learn more about. As we wrap up this mini-series, we can't help but take a long view of equality, justice, and rights in medicine. We're thankful to the amazing medical scientists trying to turn the tide today. Our guest Dr. Barbara Vanderhyden is one of those people. She's the inaugural Corinne Boyer Chair in Ovarian Cancer Research at the University of Ottawa and a Senior Scientist in the Cancer Therapeutics Program at the Ottawa Hospital Research Institute. She loves talking about her research, which focuses on how risk factors affect the incidence of ovarian cancer, and how good models of ovarian cancer can shed light on cancer susceptibility, tumour progression and response to treatment. Dr. Vanderhyden teaches about science, academic integrity, and science communication. Relevant links: Ovarian Cancer Canada Please listen, subscribe, rate, and review this podcast and share it with others. If you appreciate this content, if you want to get in on the efforts to build a gender equal Canada, please donate at canadianwomen.org and consider becoming a monthly donor. Episode Transcripts Facebook: Canadian Women's Foundation Twitter: @cdnwomenfdn LinkedIn: The Canadian Women's Foundation Instagram: @canadianwomensfoundation
May 5, 2023 Ep 450 - Fighting Cancer with CAR-T Cells Guest: Sarah Roth By Stuart McNish Cancer – there are more than 200 different types. The odds are high that you or someone you know will get cancer. It is an insidious disease; it can start almost anywhere in your body and spread. Stopping its spread is the work of cancer researchers all over the world and experts in British Columbia are developing breakthroughs. Recently a multi-site Phase-I clinical trial, launched by BC Cancer and the Ottawa Hospital Research Institute, of made-in-Canada chimeric antigen receptor T-cells demonstrated positive results. CAR-T cells are powerful new tools for treating cancer that are created by genetically modifying a person's existing T-cells. These T-cells are being used to target CD19, a protein marker found on all B-cells in patients with leukemia and lymphoma. Phase-II will allow BC Cancer to produce the CAR-T cell product and run the trial for 20 patients in BC over the next two years. Dr. Brad Nelson, director of Deeley Research Centre, says, “Over the next several years, BC Cancer's CAR-T cell program will expand beyond leukemia and lymphoma to create new and improved treatments for a wide spectrum of cancers.” Sarah Roth, the CEO of the BC Cancer Foundation, says, “The Deeley Research Centre in Victoria is a world pioneer in immunotherapy, harnessing the body's own immune system to prevent, control and eliminate cancer – and has already revolutionized cancer care.” We invited Sarah Roth to join us for a Conversation That Matters about the many research projects underway in British Columbia that will help us defeat cancer. Join me May 16 for Conversations Live - A Vancouver Sun Town Hall: Life Sciences - BC's Innovation Future https://www.conversationslive.ca/
Un nouvel épisode du Pharmascope est maintenant disponible! Dans de ce 111ème épisode, Sébastien, Nicolas et Isabelle terminent leur série sur le processus de décision partagée, cette fois en discutant des avantages, des obstacles et des moyens de l'appliquer au quotidien à l'aide d'outils. Les objectifs pour les épisodes 110 et 111 sont les suivants: Définir le processus de prise de décision partagée Identifier les bénéfices et les inconvénients du processus de décision partagée Appliquer un processus de décision partagée Ressources pertinentes en lien avec l'épisode Stacey D et coll. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431. Coronado-Vázquez V et coll. Interventions to facilitate shared decision-making using decision aids with patients in Primary Health Care: A systematic review. Medicine (Baltimore). 2020;99:e21389. Outils d'aide à la décision partagéeMcCormack J, Pfiffner P. The absolute CVD Risk / Benefit Calculator. 2017. PEER. Comparing Treatment Options for Pain: The C-TOP Tool. Mayo Foundation for Medical Education and Research. Bone Health Choice Decision Aid. 2023. BMJ Publishing Group. BMJ Rapid Recommendations. 2023. The Ottawa Hospital Research Institute. Patient Decision Aids. 2022. Primary Health Tasmania. Medication Management - deprescribing. 2023.
According to the National Association of Anorexia Nervosa and Associated Disorders, eating disorders are among the deadliest mental health illnesses in the United States. What's more, these disorders can go undiagnosed for years, making treatment and recovery even more challenging. In this interview, Gregory Hundemer, MD, an associate scientist with the Ottawa Hospital Research Institute and Assistant Professor at the University of Ottawa, provides an overview of eating disorders and discusses new research he was involved with that could help with early diagnosis and intervention. About the Expert Gregory Hundemer, MD, is an associate scientist in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute, an assistant professor of medicine at the University of Ottawa, and a staff nephrologist at the Ottawa Hospital. He received his medical doctorate from Vanderbilt University and Master of Public Health degree from Johns Hopkins University. After medical school, he served 4 years as a flight surgeon in the United States Air Force. He then completed his internal medicine residency at Massachusetts General Hospital and nephrology fellowship at the combined Massachusetts General Hospital and Brigham & Women's Hospital Joint Nephrology Fellowship Program.
The applications of large multiplex panels for detection of pathogens have greatly expanded in the past several years. Initial tests were for detection of respiratory viruses, and the first such test was labor intensive and vulnerable to frequent contamination. Since then, additional sample types have been added, such as cerebrospinal fluid and positive blood culture broths, and tests are easier to perform and reasonably reliable. We discuss a research use only multiplex PCR assay for detection of pathogens in joint infections, and learning how it compares to targeted metagenomic sequencing and culture for detection of pathogens in periprosthetic joint infections. Guests: Dr. Marisa Azad - Assistant Professor of Medicine in the Division of Infectious Diseases at The Ottawa Hospital and an Associate Clinical Scientist at the Ottawa Hospital Research Institute. Dr. Robin Patel - Co-Director of the Bacteriology Laboratory at the Mayo Clinic, where she is Professor of Medicine and Professor of Microbiology. This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro. Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript.
The SOGC Women’s Health Podcast / Balado sur la santé des femmes de la SOGC
Disclaimer: The views and opinions expressed during this podcast are those of the physicians participating and do not necessarily reflect the position of the SOGC. Access to safe, voluntary family planning is a human right because it is essential for promoting gender equality, advancing the autonomy of women and reducing poverty. In this episode, our host Dr. Graeme Smith speaks with Dr. Amanda Black about coercion free contraceptive care and how access to safe and voluntary family planning improves patient outcomes. Dr. Black is one of one of the authors of the SOGC committee opinion on Coercion Free Contraceptive Care that was published in the September 2021 edition of the JOGC. Additional Resources SOGC website: www.sogc.org Committee Opinion No. 419: Coercion Free Contraceptive Care: https://www.jogc.com/article/S1701-2163(21)00502-8/fulltext About Dr. Amanda Black Dr. Black is a Professor of Obstetrics and Gynaecology at the University of Ottawa. She works at the Ottawa Hospital and the Children's Hospital of Eastern Ontario. She completed medical training at the University of Western Ontario, University of Ottawa, and Queen's University and holds a Masters of Public Health from Johns Hopkins University. She is an Associate Scientist at the Ottawa Hospital Research Institute and is the Dr. Elaine Jolly Chair in Women's Health Research. Dr. Black has taken on many roles at the local, provincial, and national level including leadership roles within the SOGC where she is a member of the SOGC Board of Directors. She chaired the National Contraception Awareness Program for 10 years and is current Chair of the SOGC's Sexual Health and Reproductive Equity (SHARE) Committee. Dr. Black has authored many national guidelines, and has published in the areas of pediatric gynecology, contraception, and obstetrics. She is recognized nationally and internationally for her clinical expertise, providing expertise to the Public Health Agency of Canada, Health Canada, and Statistics Canada, and has represented Canada at both the CDC and WHO in the development of the Medical Eligibility Criteria for Contraception.
Sabrina Gregoire, a student at the University of Ottawa, interviews Dr. John Bell on behalf of her team for the TMM4950 Science Communication Course. Dr. Bell is a Senior Scientist in the Cancer Therapeutics Program at the Ottawa Hospital Research Institute. He is also the program director of the Canadian Oncolytic Virus Consortium and a Professor in the Departments of Medicine and Biochemistry, Microbiology, and Immunology at the University of Ottawa. In this episode, Dr. Bell discusses his research interests and ongoing projects, how cancer-killing viruses work, the advantage of this therapeutic strategy over conventional methods, and its potential for translation into clinical treatment. Learn more: https://www.ohri.ca/profile/jbell Sabrina Gregoire (Voice, Content generation), Sandra Fang (Post-production, Content generation), Marcelle Mackenzie (Content generation), and Floriana Maswa (Content generation). 1:02 - Research interests and ongoing projects4:18 - How oncolytic viruses differentiate between healthy and cancerous cells6:43 - Using the prime + boost technique in anti-cancer vaccines9:07 - Co-administrating peptide with oncolytic viruses vs. Engineering oncolytic viruses to encode peptide10:50 - Advantage of oncolytic viruses over conventional methods12:48 - Clinical translation of oncolytic viruses Soundtrack by the Underground Drive. All rights reserved. Listen more: https://music.apple.com/ca/artist/the-underground-drive/1571062779 https://open.spotify.com/artist/4sCJG8TMQyTZ9FDd1JjJmR
TMM student Rohan Ray interviews professor and scientist Dr. Michele Ardolino at the Ottawa Hospital Research Institute. Dr. Ardolino is an immunology expert and is highly established in this field, with many publications in top scientific journals. One of his studies that is discussed in this podcast is leukemia. In leukemia, a theft between cells called trogocytosis equips blood cancer cells for victory against the immune system. Learn more: https://www.ohri.ca/profile/mardolinoRagav Chona (Content Generation, Editor & Producer), Alyanna Popatia (Content Generation & Producer), Rohan Ray (Voice), Salman Abdisalam (Pre-Production) 00:48 - What sparked Dr. Ardolino's interest in the field06:14 - Dr. Ardolino's explanation of trogocytosis10:32 - Credits that thinking and luck is needed for new discoveries!13:15 - Collaboration is key!Soundtrack by Oleksii Kaplunskyi (LesFM) all rights reserved. Listen more https://bit.ly/2Jr35tF https://spoti.fi/2L952eF
Shafik and Rachel from the University of Ottawa interview Dr. Manoj Lalu. Dr. Lalu is an associate scientist from the Ottawa Hospital Research Institute and an associate professor at the University of Ottawa. He is also a co-leader of the Blueprint team, a research team aiming to improve the translation of preclinical to clinical research. Dr. Lalu is with us today to discuss his ongoing research monitoring the first Canadian multicentric preclinical study investigating a wide range of treatments against sepsis. Dr. Lalu shares with us his discoveries on the factors that can help preclinical scientists work with other labs successfully. Learn more: https://www.ohri.ca/profile/mlalu Shafik Algharbi (Voice), Rachel Friesen (Voice), Arvin Zaker (Post-production), Osama Mahdi (Post-production)00:00 - Introduction03:01 - Description of the research03:48 - Existing barriers of multi-centric research05:49 - Benefits of multi-centric research07:33 - The thing that surprised Dr. Lalu in his study09:07 - Drawbacks of multi-centric research10:07 - Suggestions for scientists11:14 - OutroMusic by Coma-Media from Pixabay
Nicole Chu from the University of Ottawa interviews Dr. Duncan Stewart. Dr. Stewart serves as the CEO and Scientific Director of the Ottawa Hospital Research Institute, and the Executive Vice-President of Research at The Ottawa Hospital. He is also an active senior scientist in The Ottawa Hospital's Regenerative Medicine Program who holds the Evelyne and Rowell Laishley Chair and is a Professor in the Department of Medicine at the University of Ottawa. Dr. Stewart is recognized as a pioneering Canadian cardiovascular researcher for his discoveries in blood vessel biology. In this episode, Dr. Stewart shares with us his research, his ongoing clinical trials, and his focus on translating benchside research into clinical treatments for patients. Learn more: https://www.ohri.ca/profile/DuncanJStewart
Join Dr. Kathy Wood, PhD, RN, FAHA, FAAN, as she explores utilizing shared decision-making for your AFib patients. Leave this conversation with tools and resources to activate your patient's engagement in their AFib care. Agency for Healthcare Research and Quality (AHRQ) website for Shared Decision Making (the SHARE mnemonic): https://www.ahrq.gov/health-literacy/professional-training/shared-decision/index.html Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/484991 US hospital webpages on atrial fibrillation ablation: A potential source for misinformation: https://onlinelibrary.wiley.com/doi/abs/10.1111/jce.15606Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE): https://pubmed.ncbi.nlm.nih.gov/26108807/Provider Decision Aid Information:Univ of CO Shared Decision Making website, Colorado Program for Patient Centered Decisions: https://patientdecisionaid.org/ Ottawa Hospital Research Institute: https://decisionaid.ohri.ca/AZlist.html). Dartmouth Center for Shared Decision Making: https://www.dartmouth-hitchcock.org/shared-decision-makingACC's CardioSmart page on Shared Decision Making: https://www.cardiosmart.org/topics/decisions/shared-decisions Health IT.gov Shared Decision Making tip sheet: https://www.healthit.gov/sites/default/files/nlc_shared_decision_making_fact_sheet.pdf Patient Resources: American Heart Association (AHA) sponsored website “My Afib Experience”: https://supportnetwork.heart.org/s/myafibmain StopAFib.org patient site: https://www.stopafib.org/ Ongoing Trials:ENHANCE AF: https://clinicaltrials.gov/ct2/show/NCT04096781 Univ of Colorado' Patient Centered Decisions Research Group: https://patientdecisionaid.org/icd/atrial-fibrillation/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Nicole Chu from the University of Ottawa speaks with Dr. Mike Hildebrand, Associate Professor at Carleton University in the Department of Neuroscience and Affiliate Investigator at the Ottawa Hospital Research Institute. Tune in to learn more about their recent work published in the Journal Brain which demonstrates for the first time that spinal cord process pain signals differently in women compared to men. Learn more: https://hildebrandpainlab.com/
Welcome to IMPACT Medicom's podcast series on COVID-19 prophylaxis. In this third episode of the series, we discuss the use of COVID-19 pre-exposure prophylaxis as a strategy to protect patients with cancer who are not able to mount a sufficient antibody response to vaccination. Our Guest:Our guest is Dr. Cowan, who is an Associate Scientist at The Ottawa Hospital Research Institute and Assistant Professor at The University of Ottawa. Dr. Cowan is also cross-appointed as an Assistant Professor at the Department of Biochemistry, Microbiology and Immunology and a Physician for the Division of Infectious Diseases at The Ottawa Hospital in Ontario. Her clinical and research focus is on prevention of infection in immunocompromised patientsSponsored by AstraZeneca CanadaIf you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
The Cochrane programme of reviews for COVID-19 covers both the diagnosis and treatment of the disease and reviews are being updated as new evidence becomes available. Among these is a review of chest imaging for diagnosing the condition, and its fourth version was published in May 2022. We asked the lead author, Sanam Ebrahimzadeh, from The Ottawa Hospital Research Institute in Canada, to describe the latest findings in this podcast.
The Cochrane programme of reviews for COVID-19 covers both the diagnosis and treatment of the disease and reviews are being updated as new evidence becomes available. Among these is a review of chest imaging for diagnosing the condition, and its fourth version was published in May 2022. We asked the lead author, Sanam Ebrahimzadeh, from The Ottawa Hospital Research Institute in Canada, to describe the latest findings in this podcast.
Welcome to Episode 6 of CLOT Conversations from Thrombosis Canada. In this episode Dr Jameel Abdulrehman and David Airdrie are joined by Dr Gregoire Le Gal and Dr Marc Carrier, two of the authors of a recently published paper on the entitled Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. The paper was published in the Annals of internal medicine, 175(1), 29-35 https://www.acpjournals.org/doi/10.7326/M21-2981The authors discuss the results of the The SubSegmental Pulmonary Embolism (SSPE) study which was a prospective international multicenter management cohort study. The objective was to assess the rate of recurrent venous thromboembolism in patients with single or multiple isolated subsegmental pulmonary embolism without proximal deep venous thrombosis that was managed without anticoagulation. Dr. Grégoire Le Gal, is a Professor in the Department of Medicine at the University of Ottawa, the lead of the Thrombosis Program, Division of Hematology at Ottawa Hospital, and a Senior Scientist in the Ottawa Hospital Research Institute, Clinical Epidemiology Program since July 2012. He was born and trained in France. His primary research interest is the diagnosis and management of venous thromboembolism (VTE). He has 425 peer-reviewed publications in general internal medicine and specialized journals. He is the current chair of INVENT, the International Network of Venous Thromboembolism Clinical Research Networks.AndDr. Marc Carrier, the Head of the Division of Hematology at The Ottawa Hospital, a Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 1 Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa. Dr. Carrier is also president of Thrombosis Canada.See also: Thrombosis Canada Tools related to the content:Pulmonary Embolism Diagnosis: https://thrombosiscanada.ca/wp-uploads/uploads/2021/11/4.-Pulmonary-Embolism-Diagnosis_14November2021.pdfPulmonary Embolism Treatment: https://thrombosiscanada.ca/wp-uploads/uploads/2021/10/5.-Pulmonary-Embolism-Treatment_27Sept2021.pdfPulmonary Embolism Management tool:https://thrombosiscanada.ca/tools/?calc=vivomap261Follow us on Twitter:Dr Grégoire Le Gal : @GrelegalDr Marc Carrier: @MarcCarrier1Thrombosis Canada: @ThrombosisCan Reference: Le Gal, G., Kovacs, M. J., Bertoletti, L., Couturaud, F., Dennie, C., Hirsch, A. M., ... & SSPE Investigators. (2022). Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation: A Multicenter Prospective Cohort Study. Annals of internal medicine, 175(1), 29-35.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
In this conversation Amy Hsu PhD, Scientist at Bruyère Research Institute, and Faculty Member of Family Medicine in Ottawa, and Peter Tanuseputro MHSc, MD, CCFP, FRCPC, Public Health Physician at the Bruyère Research Institute and the Ottawa Hospital Research Institute discuss AI enabled compassionate end of life care through their life expectancy calculator Project Big Life. Dr. Amy Hsu, PhD: Scientist at Bruyère Research Institute in Ottawa and a Faculty Member in the Department of Family Medicine in Ottawa. Amy holds the University of Ottawa Brain and Mind- Bruyère Research Institute Chair in Primary Health Care in Dementia. Dr. Peter Tanuseputro, MHSc, MD, CCFP, FRCPC: Public Health Physician and Family Physician at the Bruyère Research Institute and the Ottawa Hospital Research Institute. RESPECT: Risk evaluation for support predictions for elder life in the community tool OSSU: Ontario Spor Support Unit CIHR: Canadian Institutes of Health Research RESPECT (Life expectancy calculator): https://www.projectbiglife.ca/ - Project Big Life has developed 4 additional calculators; dementia, elder-life, heart attack and stroke, and sodium measurements. CMAJ paper Additional resource about end-of-life care Tool to plan a conversation about death with your loved ones over dinner: https://deathoverdinner.org/
In this episode we are joined by Dr Vicky Tagalakis and Dr Marc Carrier, two of the authors of a recently published review paper entitled Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. The paper was published in Current Oncology (Curr. Oncol. 2021, 28, 5434–5451. https://www.mdpi.com/1718-7729/28/6/453). The authors speak about why this update was undertaken and discuss many of the challenging scenarios encountered with this patient group and the recommendations for managing them. Join us for this insightful discussion that can help you in managing patients with cancer at risk of thrombosis.Dr. Vicky Tagalakis, is an Associate Professor of Medicine at McGill University and an attending in the Department of Medicine of the Jewish General Hospital. She is Director of the Division of General Internal Medicine at McGill University. She is a Research Scientist in the Centre of Epidemiology and Community of Studies, Lady Davis Institute for Medical Research, Jewish General Hospital. She holds several peer-reviewed grants. She is Co-Lead of the Quality Improvement Platform of CanVECTOR), a CIHR funded national research network on venous thromboembolism (VTE).Dr. Marc Carrier, is the Head of the Division of Hematology at The Ottawa Hospital, a Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 1 Research Chair in Venous Thromboembolism and Cancer from the Faculty of Medicine at the University of Ottawa. Dr. Carrier is also president of Thrombosis Canada.Related Thrombosis Canada resources:Downloadable PDF Algorithm: https://thrombosiscanada.ca/cat-treatment-algorithm-2021/DOAC Drug-Drug-Interaction tool: Download HereThrombosis Canada Cancer-associated Thrombosis (CAT) Clinical Guide: Download HereThrombosis Canada Clinical Guides: Visit HereFor other relevant resources, education programs and patient materials visit https://thrombosiscanada.caSupport the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada
Nogle nationer lader til at blæse på det, der hedder Ydre Rum Traktaten, som bestemmer, at udnyttelse af rummet skal være til gavn for alle lande. De har indført deres egne love, der giver dem mulighed for at udvinde ressourcer i rummet, og det har skabt en hårdknude i den juridiske debat om minedrift i rummet. Vi undersøger hvad hårdknuden går ud på, og hvordan den kan løses. Hør også om et nyt studie, som viser at der bliver ødelagt overraskende mange blodceller i astronauternes kroppe, når de er i rummet. Til sidst får vi en opdatering på Webb-teleskopet, som er nået frem til sin parkeringsplads 1,6 millioner kilometer fra Jorden. Medvirkende: Line Drube, Projekt-koordinator på DTU Space, Emilie Marley Siemssen, rumjurist hos satellit-producenten GomSpace, Nikola Schmidt, lektor i politikvidenskab på universitetet i Prag, Martin Švec, Ph.D. i internationale studier på universitetet i Prag, Guy Trudel, professor i medicin på Ottawa Hospital Research Institute, Peter Norsk, tidligere chefforsker på NASAs Johnson Space Center, Thomas Greve, Professor på DTU Space See omnystudio.com/listener for privacy information.
In this conversation Ed Spilg, Geriatrician at the Ottawa Hospital and Research Chair in Physician Wellness at the University of Ottawa and an AMS Phoenix Fellow and Cynda Rushton, a Nurse and Professor of Bioethics and Nursing and Medicine at Johns Hopkins University discuss moral distress, moral resilience, and mental health in healthcare workers amidst the Covid 19 Pandemic. If you would like more information on Ed and Cynda and the important work that they are doing here are some links to get you started. Ed Spilg Geriatrician in the Division of Geriatric Medicine at the Ottawa Hospital, Assistant Professor and Research Chair in Physician Wellness in the Department of Medicine at the University of Ottawa, Senior Clinical Investigator in the Clinical Epidemiology Program at the Ottawa Hospital Research Institute, and an AMS Phoenix Fellow Cynda Rushton Anne and George L. Bunting Professor of Clinical Ethics in the Johns Hopkins Berman Institute of Bioethics and the School of Nursing with a joint appointment in the School of Medicine's Department of Pediatrics Book Rushton, C. H. (Author & Ed) (2018) Moral Resilience: Transforming Moral Suffering in Healthcare. New York: Oxford University Press. (American Journal of Nursing/Elsevier Book of the Year First Place Award in the category of professional issues 2020). https://tinyurl.com/2h6ez5bu Resources for clinicians https://link.springer.com/article/10.1186/s12888-021-03637-w https://tinyurl.com/bde6uuu9 https://www.cma.ca/physician-wellness-hub https://www.cma.ca/sites/default/files/pdf/Moral-Distress-E.pdf AACN Facebook Live: I'm not ok—Dealing with the baggage of a prolonged pandemic Mind the Gap Rushton Moral Resilience Scale Moral Stress Amongst Healthcare Workers DURING COVID-19: A Guide to Moral Injury. Centre of Excellence on PTSD, 2020. https://www.moralinjuryguide.ca/
Expanding a medical practice is both exciting and challenging. In this interview, Dugald Seely, ND, FABNO, describes why and how he expanded his highly specialized oncology clinic to create The Center for Health Innovation in Ottawa, Canada. There are many aspects to consider when expanding a clinical focus and it's always helpful to learn those valuable lessons from someone who has done it successfully. About the Expert Dugald Seely, ND, MSc, FABNO, runs a clinical practice with a multidisciplinary team of healthcare practitioners at the Centre for Health Innovation (home of the Ottawa Integrative Cancer Centre). Seely is the executive director for the Patterson Institute for Integrative Oncology Research at the Canadian College of Naturopathic Medicine as well as serving as an affiliate investigator for the Ottawa Hospital Research Institute, and adjunct professor with the School of Epidemiology and Public Health at the University of Ottawa. Seely completed his master of science in cancer research at the University of Toronto and has been awarded over 11 million dollars in grant research funding. Past-president for the Oncology Association of Naturopathic Physicians and recipient of the 2017 Rogers Prize, Seely aims to build on the evidence for naturopathic oncology and the practice of integrative oncology as a whole.
Do you have asthma? It is extremely common, about three million Canadians have been diagnosed with the condition. But researchers now say if you are one of them, you should double-check. A study led by the Ottawa Hospital Research Institute found that fully a third of adults being treated for asthma don
Libby Znaimer is joined by Conservative MP Michael Chong (Wellington-Halton Hills) and the Conservative Shadow Minister for Foreign Affairs followed by Annamie Paul (Toronto Centre), Leader of the Green Party of Canada and then Bob Richardson, Liberal strategist and Senior Council to National PublicRelations. Ottawa has entered a legal battle over Enbridge's Line 5 pipeline that is an important energy source for Ontario and Quebec. The federal government has gone as far as to say that a shutdown of the pipeline would "harm" the relationship between Canada and the U.S. and be contravening to a 1977 treaty. Meanwhile, Enbridge is continuing operations of Line 5 against Michigan Governor Gretchen Whitmer's May 12 deadline for a shutdown. Our leaders weigh in on the latest diplomatic crisis. ---- STUDIES SHOW THAT MIXING VACCINE DOSES INCREASES SYMPTOMS Libby Znaimer is joined by Dr. Kumanan Wilson, epidemiology researcher and medical professor at the Ottawa Hospital Research Institute and Dr. Iris Gorfinkel, a family physician and founder of PrimeHealth Clinical Research. New findings from a U.K. Study indicate that mixing the two vaccine doses can lead to an increase in symptoms like fever, and fatigue. Our health experts weigh in on the latest. ---- DR. LAWRENCE LOH UPDATES US ON PEEL REGION'S COVID-19 RESPONSE AND VACCINE ROLLOUT Libby Znaimer is joined by Dr. Lawrence Loh, Medical Officer of Health for the Region of Peel. Dr. Loh has developed a reputation for implementing bold measures to help curb the spread of COVID-19 in the region of peel-one of the hardest hit regions in the province. One of the more recent things he's done is impose a closure on business operations with links to at least 5 cases of COVID-19. In addition to strict measures, he's also had a good track record of sticking to consistent public health messaging which contrasts the confused and messy communication of our other public health officials. Dr. Loh joins Fight Back to detail the challenges that lie ahead for Peel Region, and the province as a whole, and provides some additional clarification on the province's decision to pause the first dose of AstraZeneca. He also weighs in on the recent findings in a U.K. study that reveal that mixing vaccine doses can escalate symptoms like fatigue and fever and whether we should be concerned about this. Listen live, weekdays from noon to 1, on Zoomer Radio!
Jennifer Cox, Manager, Research Contracts at Ottawa Hospital Research Institute (OHRI), dives into the legal challenges associated with virtual trials, remote monitoring, digitalized patient info, and cross-border collaborations in the time of COVID-19.Schedule a meeting with Natalie Yeadon: https://www.meetwithnatalie.comNatalie Yeadon LinkedIn: https://www.linkedin.com/in/natalieyeadon/Impetus Digital Website: https://www.impetusdigital.com/Impetus Digital LinkedIn: https://www.linkedin.com/company/impetus-digital/Impetus Digital Twitter: https://twitter.com/ImpetusadboardsImpetus YouTube: https://www.youtube.com/ImpetushealthcareJennifer Cox: https://www.linkedin.com/in/jen-cox-008a62bb/Ottawa Hospital Research Institute (OHRI): http://www.ohri.ca/home.asp
Our programme of rapid reviews for COVID-19 covers both the diagnosis and treatment of the disease and the reviews are being updated as new evidence becomes available. Among these is a review on imaging tests for diagnosing the condition, and we asked the lead author of the March 2021 update, Nayaar Islam from The Ottawa Hospital Research Institute in Canada, to describe the latest findings in this podcast.
Our programme of rapid reviews for COVID-19 covers both the diagnosis and treatment of the disease and the reviews are being updated as new evidence becomes available. Among these is a review on imaging tests for diagnosing the condition, and we asked the lead author of the March 2021 update, Nayaar Islam from The Ottawa Hospital Research Institute in Canada, to describe the latest findings in this podcast.
In today's episode of our International Women's Week 2021 Event, Dr. Darine El-Chaâr joins Julia Slanina to discuss how COVID-19 has changed pregnancy and giving birth.Dr. Darine El-Chaâr is an Associate Scientist, Clinical Epidemiology Program at the Ottawa Hospital Research Institute, an Assistant Professor, Department of OB/GYN at the University of Ottawa and the current program director for the Maternal-Fetal Medicine Fellowship at the Ottawa Hospital, located in Ottawa Ontario.If you want to learn more about Dr. El-Chaâr's work you can check it out at ohri.ca/profile/del-chaarIf you want to learn more about Julia's work check it out at treehousemedical.caIf you're a provider and are interested in the Treehouse Medical Early Access Program you can check it out at treehousemedical.ca/eap See acast.com/privacy for privacy and opt-out information.
http://feeds.soundcloud.com/users/soundcloud: NIA IMPACT Collaboratory/sounds.rss
Stuart Nicholls, PhD, from the Clinical Epidemiology Program at the Ottawa Hospital Research Institute ,continues the discussion from his February 18 Grand Rounds presentation. This discussion with IMPACT Principal Investigator Susan Mitchell, MD, MPH answers questions from Dr. Nicholls's presentation on giving an overview of ethical issues raised by pragmatic randomized controlled trials (RCTs) and which derive from ongoing work to develop guidance for those designing and conducting pragmatic RCTs.
La pandemia de covid-19 está dificultando el diagnóstico de la enfermedad, así como su tratamiento, pero las revisiones rápidas preparadas por Cochrane cubren ambas áreas. A continuación se describen los últimos hallazgos de la revisión actualizada en noviembre de 2020, cuyo autora principal es Nayaar Islam del Ottawa Hospital Research Institute en Canadá, acerca del uso de pruebas de diagnóstico por imagen para detectar la covid-19. Este podcast ha sido traducido por Andrea Cervera y locutado por Montse León del Centro Cochrane Iberoamericano.
La pandemia de covid-19 está dificultando el diagnóstico de la enfermedad, así como su tratamiento, pero las revisiones rápidas preparadas por Cochrane cubren ambas áreas. A continuación se describen los últimos hallazgos de la revisión actualizada en noviembre de 2020, cuyo autora principal es Nayaar Islam del Ottawa Hospital Research Institute en Canadá, acerca del uso de pruebas de diagnóstico por imagen para detectar la covid-19. Este podcast ha sido traducido por Andrea Cervera y locutado por Montse León del Centro Cochrane Iberoamericano.
The COVID-19 pandemic is creating challenges for diagnosis of the disease, as well as for its treatment. The rapid reviews being prepared and updated by Cochrane are covering both areas. We asked the lead author of the November 2020 versions of our review of the evidence on using imaging tests to diagnose the condition, Nayaar Islam from The Ottawa Hospital Research Institute in Canada, to describe the latest findings in this podcast.
The COVID-19 pandemic is creating challenges for diagnosis of the disease, as well as for its treatment. The rapid reviews being prepared and updated by Cochrane are covering both areas. We asked the lead author of the November 2020 versions of our review of the evidence on using imaging tests to diagnose the condition, Nayaar Islam from The Ottawa Hospital Research Institute in Canada, to describe the latest findings in this podcast.
This podcast is a review of the Canadian Pediatric Society's position statement on postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia in preterm infants. It was developed by Dr. Amélie Cyr, a pediatric resident at the University of Saskatchewan with Drs. Brigitte Lemyre, Michael Dunn, Bernard Thébaud, the principle authors of the statement. Dr. Brigitte Lemyre is a clinical investigator and an academic neonatologist at the Children's Hospital of Eastern Ontario (CHEO) and at the Ottawa Hospital. Dr. Michael Dunn is a neonatologist at Sunnybrook Health Science in Toronto and Dr. Bernard Thébaud is a senior scientist with the Ottawa Hospital Research Institute and a neonatologist at CHEO and the Ottawa Hospital.
La pandemia de covid-19 está planteando retos para diagnosticar la enfermedad, así como para tratarla, pero las revisiones rápidas preparadas por Cochrane cubren ambas áreas. Este podcast describe los hallazgos de la revisión publicada en septiembre de 2020, cuyo autor principal es Jean-Paul Salameh del Ottawa Hospital Research Institute en Canadá, acerca del uso de pruebas de diagnóstico por la imagen para detectar esta enfermedad. Este podcast ha sido traducido por Andrea Cervera y locutado por Montse León del Centro Cochrane Iberoamericano.
La pandemia de covid-19 está planteando retos para diagnosticar la enfermedad, así como para tratarla, pero las revisiones rápidas preparadas por Cochrane cubren ambas áreas. Este podcast describe los hallazgos de la revisión publicada en septiembre de 2020, cuyo autor principal es Jean-Paul Salameh del Ottawa Hospital Research Institute en Canadá, acerca del uso de pruebas de diagnóstico por la imagen para detectar esta enfermedad. Este podcast ha sido traducido por Andrea Cervera y locutado por Montse León del Centro Cochrane Iberoamericano.
The COVID-19 pandemic is creating challenges for diagnosis of the disease, as well as for its treatment and the rapid reviews being prepared by Cochrane are covering both of these areas. We asked the lead author of the September 2020 review of the evidence on using imaging tests to diagnose the condition, Jean-Paul Salameh from The Ottawa Hospital Research Institute in Canada, to describe their findings in this podcast.
The COVID-19 pandemic is creating challenges for diagnosis of the disease, as well as for its treatment and the rapid reviews being prepared by Cochrane are covering both of these areas. We asked the lead author of the September 2020 review of the evidence on using imaging tests to diagnose the condition, Jean-Paul Salameh from The Ottawa Hospital Research Institute in Canada, to describe their findings in this podcast.
Ottawa Hospital Research Institute's Dr. Doug Manuel sifts through the coronavirus numbers worldwide, discusses who's doing well and who's not, and lays out what Canada needs to do to puncture the rising trend.
Ottawa Hospital Research Institute's Dr. Doug Manuel sifts through the coronavirus numbers worldwide, discusses who's doing well and who's not, and lays out what Canada needs to do to puncture the rising trend.
Dr. Kyeremanteng is a Critical Care Physician at the Ottawa Hospital and Montfort Hospital, a Senior Clinician Investigator at the Ottawa Hospital Research Institute, and an associate professor in the division of Palliative Care at the University of Ottawa. He completed medical school at the University of Alberta, Internal Medicine residency and Palliative Care fellowship at the University of Ottawa, and a Master's of Health Administration at Dalhousie University. Dr. Kyeremanteng's area of research interest is resource optimization in the ICU, and he is the host of the podcast “Solving Healthcare”.
We kick off our coverage of the Canadian Vision 2020 Summit in Ottawa! Today we discuss the state of vision research in Canada with Dr. Catherine Tsilfidis from the Ottawa Hospital Research Institute and Dr. Michel Cayouette from the Montreal Clinical Research Institute. This is the February 24th, 2020 episode.
Hallie Arnott interviews Dr. Kelly Cobey from the Ottawa Hospital Research Institute. Dr Cobey explained us the negative impact of predatory journals and "pseudo-science."
http://feeds.soundcloud.com/users/soundcloud: NIA IMPACT Collaboratory/sounds.rss
IMPACT Collaboratory PI Vince Mor sits down with Monica Taljaard, PhD to dive deeper into her recent IMPACT Collaboratory Grand Rounds presentation of stepped wedge cluster randomized trials. Taljaard, Senior Scientist at Ottawa Hospital Research Institute, is a biostatistician specializing in the design, analysis and ethics of pragmatic cluster randomized and stepped wedge trial.
This week, a closer look at the role journals both prestigious and predatory play in science and academia. Dr David Moher, Director of the Centre for Journalology at Canada's Ottawa Hospital Research Institute, joins Ray to explore the way publication practices and the 'publish or perish' mentality shape researchers' careers and the research agenda more broadly.
Do you have asthma? It is extremely common, about three million Canadians have been diagnosed with the condition. But researchers now say if you are one of them, you should double-check. A study led by the Ottawa Hospital Research Institute found that fully a third of adults being treated for asthma don
"Pro: Regional Anesthesia and Pain Medicine Specialists Should Help Train Non-Anesthesia Specialists to Perform Peripheral Nerve Blocks," by Peter Rose, MD, MSc, FRCPC, University of Ottawa, Ottawa Hospital Research Institute, University of British Columbia, and Michael Woo, MD, University of Ottawa and Ottawa Hospital Research Institute, Canada."Con: Regional Anesthesia and Pain Medicine Specialists Should Not Help Train Non-Anesthesia Specialists to Perform Peripheral Nerve Blocks," by Reva Ramlogan, MD, FRCPC, The Ottawa Hospital, Canada, and Rafael Nascimento, MD, Americas Medical City, Rio de Janeiro, Brazil. From ASRA News, February 2019, pp. 13-16. See original article at www.asra.com/asra-news for figures and references. This material is copyrighted.
Dr Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts. I'm Dr Carolyn Lam, associate editor from the National Heart Center and Duke National University of Singapore. Dr Greg Hundley: And I'm Greg Hundley, associate editor and director of the Pauley Heart Center at VCU Health, in Richmond, Virginia. Dr Carolyn Lam: So Greg, are ARNI's now going to be used for functional, mitral regurgitation and heart failure? Well, we're going to be chatting all about that with our feature paper, coming right up after these summaries. Greg, you've got a biggie to start with, haven't you? Dr Greg Hundley: Oh yes, Carolyn, I'm really excited about this paper. The senior author Wanpen Vongpatanasin from University of Texas Southwestern Medical Center in Dallas and looking at high phosphate diets and their relationship to exercise intolerance. I really felt this was an exceptional study and combining that key that we have, for basic science papers and translation, where we're looking at data from both human and basic science, in both in a single manuscript. So, this study focuses on inorganic phosphates and they are present in 40-70 percent of the foods, really as a preservative enhancer, in western diets. We see it in colas, meats, dry food mixes, bakery products. For the human subject component of this study, the investigators examine the relationship between physical inactivity, assessed with ActiGraphs that were worn, and serum phosphate levels. They also obtained MRI measures of cardiac function and participants were recruited from the Dallas Heart Study too. In animals, they looked at the direct effects of dietary, inorganic phosphate on exercise capacity, oxygen uptake, serum non-esterified fatty acids, and glucose was measured during exercise treadmill tests in mice fed either high inorganic phosphate diets or normal in-organic phosphate diets. And they were on that for 12 weeks. To determine the direct effect of phosphate on muscle metabolism and expression of genes involved in fatty acid metabolism, additional studies in the differentiated myotubes were conducted after subjecting those cells to media with high or low phosphate conditions. Dr Carolyn Lam: So, what did the study show? Dr Greg Hundley: In the human part, among 1603 participants, higher serum in-organic phosphate was independently associated with reduced time spent in moderate to vigorous physical activity and increased sedentary time. And interestingly, there was no association between serum phosphate levels and left ventricular ejection fraction or volumes. In the animal studies, mechanistic insight was obtained. Compared to controlled diets, consumption of high phosphate diet for 12 weeks did not alter body weight or left ventricular function, thereby confirming what we saw in the human subjects, but reduced maximal oxygen uptake, treadmill duration, spontaneous locomotor activity, fat oxidation, fatty acid levels, and led to down-regulations of genes involved in fatty acid synthesis. So, the take-home on this is that the results of this study demonstrate a detrimental effect of dietary, phosphate excess on skeletal muscle, fatty acid metabolism, and exercise capacity, which is independent of obesity and cardiac contractile function. And as such, dietary in-organic phosphate may represent a novel and modifiable target to reduce physical inactivity associated with the western diet. I think, Carolyn, we're going to see a large number of epidemiologic studies that are going to really look at this as something we might be able to modify in our diet to help impact some of these sedentary lifestyles and the harmful cardiovascular effects that we find associated with that lifestyle. Dr Carolyn Lam: Yikes. Remind me again, so phosphates in colas, meats, dried food mixes, and bakery products and so on, the preservative. Wow, you're right; big paper. Dr Greg Hundley: It's amazing. It's in 40-70 percent of the food products here in the United States. So, wow. Something really striking. So Carolyn, how about one of the papers that you liked? Dr Carolyn Lam: Moving to related cardio metabolic disease, we know that patients with type 2 diabetes and prevalent atherosclerotic cardiovascular disease, there is a tenfold variation in future cardiovascular risk in these patients. The current paper actually analyzes data from EMPA-REG OUTCOME where the authors, led by David Fitchett from St. Michael's Hospital in Toronto, sought to investigate whether the beneficial effects of Empagliflozin, observed in the EMPA-REG OUTCOME trial, varied across the spectrum of baseline, cardiovascular risk. What they found was that in patients with type 2 diabetes and atherosclerotic cardiovascular disease, the relative reductions in risk of cardiovascular death, all-cause mortality, 3-point MACE, and heart failure hospitalizations with Empagliflozin versus placebo, were consistent in patients with and without a prior, myocardial infarction, with and without a prior stroke, and across sub-groups by the 10-point TIMI Risk Score for secondary prevention at baseline. Dr Greg Hundley: Does this suggest, Carolyn, that we use these inhibitors in all patients with type 2 diabetes? Dr Carolyn Lam: Remember the EMPA-REG OUTCOME; all patients had established atherosclerotic cardiovascular disease. This paper really adds to the understanding of the gradient of risk within these patients who had atherosclerotic cardiovascular disease and says Empagliflozin could be beneficial. But remember, there are patients with type 2 diabetes without established, cardiovascular disease and I think there's still equipoise in this primary prevention population. Dr Greg Hundley: That was great, Carolyn. Now I'm going to grab another sip of coffee and go onto my next paper. Dr Carolyn Lam: Sure, as long as it's not cola. No phosphates. Dr Greg Hundley: Right, thank you very much, Carolyn. I'm going to talk about screening for small and medium abdominal aortic aneurysms. This particular study comes from the surveillance of the National Health Service screening program by Dr Earnshaw. Basically, population screening for abdominal, aortic aneurysms has been shown to reduce AAA-related mortality by up to 50%. Most men who screen positive have a AAA below 5.5 centimeters in diameter, and that's really our current referral threshold for treatment. When they have smaller diameter aneurysms they're entered into an ultrasound surveillance program. In this study, the investigators looked and reviewed those that had small, 3-4.4 centimeter diameter aneurysms or medium ,4.5 up to 5.4 centimeter aneurysms, and they were followed. They were looking at the risk of rupture in these under surveillance. They had a total of 18,652 men and the risk of rupture overall per annum was 0.03% for men with small, abdominal aortic aneurysms and 0.28% for medium size. That was just below the threshold for the 5-5.4 centimeters, which was 0.4% over time. The risk of abdominal aortic aneurysm surveillance is below .5% per year and that is just below our current referral threshold for surgery, which is 5.5 centimeters. This is a study that really confirms, Carolyn, that the target mark or diameter that we've selected is appropriate. Dr Carolyn Lam: Nice. These just confirm the current guidelines? Dr Greg Hundley: Yeah, they do and Gil Upchurch from University of Florida, a surgeon, had a very nice editorial. The point he wants to make is yep, diameter of 5.5 is the threshold, but a couple key points. As patients are coming in for these visits, we need to continue to emphasize to them other factors related to growth of abdominal aortic aneurysms and their rupture. So, tobacco cessation, treatment of your lipids, management of your hypertension. The other point that he makes, is we really don't need to be operating on those individuals with an abdominal aortic aneurysm diameter of less than 5.5 centimeters. He makes an argument here that's in some countries with fee-for-service reimbursement, up to 30% of AAA repairs are for aneurysms less than this diameter of 5.5 centimeters. This over utilization of resources can add considerable costs to the healthcare system for managing this condition and is unlikely to increase the overall survival of these patients. A nice study confirming that what we're doing, really in terms of size and diameter, is correct, but also emphasizing this patient population often has a lot of other cardiovascular co-morbidities that we need to aggressively manage. How about your next paper? Dr Carolyn Lam: From one very clinically, applicable paper to another. This one answers the question, what's the optimal duration of emergency department and post-emergency department rhythm monitoring among patients with syncope. And the authors, led by Dr Thiruganasambandamoorthy and his colleagues from the Ottawa Hospital Research Institute, prospectively studied adults presenting within 24 hours of syncope at six emergency departments. They collected baseline characteristics, the time of syncope, the time of emergency department arrival, and the Canadian Syncope Risk Score, risk category. They followed subjects for 30 days and adjudicated the primary outcome, which was serious arrhythmic conditions and that includes arrhythmias or interventions for arrhythmias and unexplained death. Their results showed that the overall arrhythmia risk, and the risk after two hours of emergency department arrival from Canadian Syncope Risk Score, low-risk patients, was indeed very low. Similarly, the overall risk and after six hours of emergency department arrival for medium and high-risk patients was moderate and high, respectively. No low-risk patients suffered ventricular arrhythmia or unexplained death and most of the arrhythmias among the non-low-risk patients occurred within 15 days of the index syncope. Dr Greg Hundley: Carolyn, what's the take home message here? Dr Carolyn Lam: The results really support brief monitoring in the emergency department for two hours for Canadian Syncope Risk Score low-risk patients, and six hours for medium and high risk patients followed by selective admissions and the results also support a 15-day outpatient monitoring for medium-risk patients at a selected threshold and for all high-risk patients. So very practical advice. Dr Greg Hundley: Very good. Until next week, I'm going to watch out for phosphates. Dr Carolyn Lam: Indeed, and let's go on now to our featured discussion. For today's featured paper, we are discussing the results of the PRIME Study and that is Angiotensin Receptor Neprilysin Inhibitor, or ARNIs, for functional mitral regurgitation. A terribly interesting study. So pleased to have with us an author Dr Sung-Hee Shin from Inha University Medical center in Incheon, Korea as well as our associate editor Dr Victoria Delgado from University of Leiden in the Netherlands. Sung-Hee, what an interesting study. ARNI or Entresto for functional mitral regurgitation. Could you tell us what inspired this study and what did you find? Dr Sung-Hee Shin: Our study was the designed to tell if ARNI or functional mitral regurgitation because secondary functional mitral regurgitation was developed as a result of a reduced function. Guideline-directed medical therapy for heart failure would be a mainstay for a therapy. But despite use of the traditional drugs such as BETA blocker, ACE inhibitor or angiotensin receptor blockers, you know that the functional mitral regurgitation may be common and significant in the person having this functional mitral regurgitation would be related to increased morbidity and mortality. So, that trial showed that trans-catheter mitral valve repair effectively reduced the function mitral patient and resulted in lower rate of heart related mortality among patients with heart failure and function mitral regurgitation. In our blind trial, we also tried to tell whether an ARNI is more effective in improving function mitral regurgitation and randomly assigned 118 patients with heart failure and chronic secondary function mitral regurgitation lasting more than six months despite medical therapy and ejection fraction between 25% and 50% to receive either sacubitril/valsartan or valsartan in addition to standard medical therapy for heart failure. What happened with that change of mitral regurgitation after 12 months which was assessed by means of transthoracic area ways echo. What we observed was that transthoracic area as well as the volume of mitral regurgitation saw a decrease much more effective in the sacubitril/valsartan group than valsartan group. We also looked at the various other measures of the left ventricle remodeling and showed that the valsartan group had smaller left ventricle volume at 12 months and had a greater reduction of end-diastolic volume index. Also, among the completers ARNI, for the reduced left ventricle volume and the yearly time than the control group. So, what we think is that these factors might contribute to greater reduction of function mitral regurgitation in patients in the sacubitril/valsartan group. But our study was a mechanism study, but it was not designed to see outcomes. So further research and data would be necessary to check is this transthoracic echo end point can translate into better outcome in this population. Dr Carolyn Lam: Sung-Hee, this is just so interesting to have hypothesized this about functional mitral regurgitation. And not only that, I mean, to my mind, this is the largest echo-based studies of patients before and after Entresto that I can think of. It's nice to know, on top of knowing in paradigm that we can improve outcomes in heart failure reduced ejection fraction, that we now can look at the heart and see what happens in so many dimensions. So, congratulations. Victoria, were you surprised by these results? And do you agree with the mechanisms that Sung-Hee suggested? Dr Victoria Delgado: I think that this study is very important because in the field of functional mitral regurgitation, there is still a lack of consensus on how to treat these patients, which are very challenging. If the patient needs revascularization they will be referred for certain. But it still should be CBR mitral regurgitation and moderate and mile mitral regurgitation are not considered. I think that we discuss often which is the optimal medical therapy or the guidelines based medical therapy but it's not really consensus because the studies before have not been like this one. That large in order to answer a specifically that question. I think that this article brings an important message and brings more evidence to our field that there is not that much data. So, I think it's very important for that research, in particularly after the research of the co-op and the mitral trial where it seems that the selection of patients is very important in order to identify the patients that will really benefit from those therapies. Dr Carolyn Lam: That's such a good point. Going to that selection of patients, Sung-He, you mentioned very carefully the ejection fractions that you allowed up to 50% in these patients. Could you explain how you reasoned the selection of this patient cohort? Dr Sung-Hee Shin: The reason why we chose the patients we did, the range of ejection fraction condition, was that we thought the reversibility of the left ventricle mortality and function mitral regurgitation might be more pronounced in these patients. When we considered the fraction condition in mitral regurgitation with ejection fraction used under [inaudible 00:18:17] LV dysfunction, our inclusive criteria of ejection fraction between 25 to 50% might correspond to ejection fraction of 20 to 40% in patients with mitral regurgitation. We concluded that if a patient had ejection fraction less than 25% because the reversibility of mortality and function mitral regurgitation might be smaller when all the LV dilation is too extreme and advanced heart failure is already established. So, I just thing how it can be provided to the patient who have functional mitral regurgitation associated with too extreme LV dilation and LV ejection fraction too. Dr Victoria Delgado: I think, Carolyn, it's a very good point what she explained because we are used to select patients based on ejection fraction, in particularly patients with functional mitral regurgitation, ejection fraction is rather misleading because actually it's just a change of volume in the ventricles emptying in a low pressure chamber which is the left atrium. The moment that you correct that in mitral regurgitation sometimes then you face, or you see, the true ejection fraction of that ventricle. And if we wait too long, we may end up with ventricles that they don't have any more resource in order to improve ejection fraction after repair of the mitral valve. So, I think that this study is important to also realize that concept. That ejection fraction in patients with functional mitral regurgitation may not be the most accurate parameter to assess the function of that ventricle. Dr Carolyn Lam: Yeah. Exactly. And I thought that was a very clever part of the design. I'm glad you explained it and also so glad, Victoria, you invited the editorial by Dr Mullens, who also commented on that. So, just for the audience to understand that ejection fraction up to 50% was included and ejection fraction less than 25% was excluded. So also, again, very consistent to your prior point, Victoria. Could I ask you, I think Dr Mullens also spent quite some time talking about the potential mechanisms. What's your take of this Victoria? ARNI for functional regurgitation. How come? Dr Victoria Delgado: For me, I'm much more from the side of the imaging point of view. When we have patients with functional mitral regurgitation I always try to see which is the capability that that ventricle has to recover. Actually, first is always medical therapy, but we know that the [inaudible 00:20:59] only, for example, we just reduced the mitral regurgitation, but they don't really improve the function of that ventricle, while if you reduce the loading conditions of the ventricle in terms of blood pressure as well and favoring remodeling of the left ventricle, you can improve the condition of the mitral valve and reduce the mitral regurgitation. How valsartan plus sacubitril works differently than valsartan alone that I don't think that I have enough knowledge to explain why but it could be that in a way there is more effective with sacubitril on top of valsartan can improve the loading conditions of the ventricle and improve the, or facilitate, the reversing of morbidity of that ventricle, reducing the mitral regurgitation and that, by itself, could also lead to reversing morbidity. Like a little bit cardiac resynchronization we'd do, for example, in patients with an ejection fraction below 35% and based on the EEG you have the synchronous fraction of the papillary muscle or the walls of the ventricle which could lead to the mitral regurgitation at the moment that you resynchronize that mitral regurgitation can produce, you reduce part of the volume of the load of the ventricle and that can favor that reversing morbidity. So, I think that this study raises a lot of questions and I think that further research is needed in order to confirm or to know more how these treatments work. Dr Carolyn Lam: Goodness, that was so beautifully explained and in fact, many clues from Sung-Hee's study and the reversal of left ventricle end diastolic volume index greater with those treated with ARNI, the LA size and so on. But maybe I should ask you, Sung-Hee, in line with what Victoria said, what are the next steps? Do you already know what are the next studies that you're going to be looking at in PRIME? Dr Sung-Hee Shin: We're considering mark of monitoring such as NT pro-BNP or using auto imaging models such as echo and cardiac MRI to look at the change of mitral valve regurgitation in more detail. This kind of study might be very helpful in understanding [inaudible 00:23:15] ARNI in functional mitral patient. Dr Carolyn Lam: Yes, that's clever, too. And Victoria, before we end could you maybe give us some take home messages? Dr Victoria Delgado: I think that the take home message from this study is that when we have patients with functional mitral regurgitation, we need to think what we can offer to them. Not consider mitral regurgitation just as a base standard. That it's going to respond only to diuretics. No. We need to do something on that left ventricle to help it to improve the function and to avoid the progress to more reduced function. It's very important to understand the mechanism of the mitral regurgitation and to use the guidelines based medical therapy trying to go step by step in order to optimize the medication of that patient and later on, see all the potential treatments that are available right now such as cardiac synchronization therapy, which we should not forget, and then surgery if the patient needs catheterization and if the patient needs the benefit from mitral valve plasty or eventually, for example, trans catheter mitral valve therapies. But we should avoid that the patient goes further down into heart failure with very dilated ventricles and very poor function because then probably we may face a point of no return. Dr Carolyn Lam: Thank you so much, Victoria. Both you and Sung-Hee mentioned this is a mechanistic study. So many insights. But it's not saying that everybody with functional mitral regurgitation has to be treated this way now. It's calling for more work and it's certainly very, very important study. Thank you listeners, for listening today as well. You've been listening to Circulation on the Run. Don't forget to tune in again next week. This program is copyright American Heart Association, 2019.
Ёвролт 17-доо өөрийгөө Монголоор овоглож явдаг микробилогич Хазара Канад охинтой хийсэн ярилцлагыг толилуулж байна. Nooria Poldia works at Biotherapeutics Manufacturing Centre in Ottawa Hospital Research Institute.
Ёвролт 17-доо өөрийгөө Монголоор овоглож явдаг микробилогич Хазара Канад охинтой хийсэн ярилцлагыг толилуулж байна. Nooria Poldia works at Biotherapeutics Manufacturing Centre in Ottawa Hospital Research Institute.
About the Interview Tina Kaczor, ND, FABNO, recently sat down with Dugald Seely, ND, MSc, FABNO, director of the Ottawa Integrative Cancer Centre, to discuss several ongoing studies in integrative oncology. Studying integrative oncology has unique study design challenges. They talked about how these challenges are met and how current study designs are attempting to accurately reflect complex in-office care. Seely covered a broad range of topics, from details of specific studies to an overview of the current landscape of collaborating with peers in integrative oncology. He also offered some tips on how private practice clinicians can begin to participate in research. The Thoracic POISE Trial One of Seely’s current research endeavors is the Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial. Seely says it’s probably the most interesting and complex study his team is currently working on. The goal of this trial is to explore the impact of naturopathic medicine in addition to conventional usual care at the hospital for patients who have thoracic cancers and are eligible for surgery. The researchers are randomizing a group of these patients into receiving standard usual care at the hospital only, or getting usual care plus an integrated approach delivered by a naturopathic doctor before surgery and for a year after surgery. They’ll be looking at a whole battery of different outcomes, including adverse events related to surgery, quality-of life-measures, immune function, inflammatory changes, cost-effectiveness, and, ultimately, long-term survival and recurrence rate over 5 years. Seely sees this study as an opportunity to investigate the effectiveness of truly holistic, whole-person care. To do that, they’ll be employing interventions in 4 domains: Targeted natural health products Nutritional approaches Fitness improvements (particularly pulmonary fitness) Mind and body medicine and psychological well-being At the end of the study, Seely expects to be able to say whether, as a whole, naturopathic medicine in this setting can make a difference in outcomes related to survival or adverse events related to surgery. Canadian/US Integrative Oncology Study Another study Seely is working on is called the Canadian/US Integrative Oncology Study. This is being done in partnership with Bastyr University. The other principal investigator is Leanna Standish, ND, PhD, LAc, FABNO. This study, which will be conducted over a 6- to 7-year period, will recruit and observe the interventions given to patients with 4 types of late-stage cancer. The researchers will look at the naturopathic care interventions given to these patients at 11 different clinics across North America. Seely and the research team are looking at clinics with the most innovative and useful therapies in naturopathic oncology. They’ll document the interventions and follow the patients to observe effects on survival rates. In addition, they’ll be looking at cost and quality of life. In the end, Seely hopes the CUSIOS trial will shed light on the outcomes we see with patients who go through these advanced integrative oncology clinics. How Can Clinicians Get Involved in Research? For clinicians interested in getting involved in research, Seely offered this guidance: Build relationships. For him, doing graduate work was key because it automatically caused him to engage and collaborate with others. If you’re interested in research, start by connecting with people at academic institutions and begin the dialog. If you’d like to learn more about the sites currently involved in integrative medicine research, visit Clinicaltrials.gov. About the Expert Dugald Seely, ND, MSc, FABNO, leads the clinical practice and cancer research program for the Ottawa Integrative Cancer Centre. In addition to his clinical role as a naturopathic doctor, he also serves as the executive director of research & clinical epidemiology at the Canadian College of Naturopathic Medicine, affiliate investigator for the Ottawa Hospital Research Institute, and vice president for the Oncology Association of Naturopathic Physicians. Seely completed his master of science in cancer research at the University of Toronto and is a fellow of the American Board of Naturopathic Oncology. As a clinician scientist, Seely has been awarded competitive grant and trainee funding from the Canadian Institutes of Health Research, the Canadian Breast Cancer Research Alliance, the SickKids Foundation, the Lotte and John Hecht Memorial Foundation, the Ottawa Regional Cancer Foundation, and the Gateway for Cancer Research Foundation. Transcript Tina Kaczor, ND, FABNO: Hello. I'm Tina Kaczor with the Natural Medicine Journal. I'm speaking today with naturopathic physician and researcher, Dugald Seely. Dr. Seely is the founder and executive director of the Ottawa Integrative Cancer Center in Ontario, Canada. He has led numerous research projects including the largest integrative naturopathic cancer care clinical trial ever conducted in North America. He has more than 50 MEDLINE indexed peer-reviewed publications. Last but not least, among his many accolades over the years, he has most recently been awarded the Dr. Rogers Prize, which is a prize awarded in Canada for excellence in complementary medicine. Dr. Seely, thanks so much for joining me today. Dugald Seely, ND, FABNO: Thanks so much for having me on to talk, Tina. Kaczor: There are so many things that we could talk about in the realm of research. You're also a practicing clinician, so there's lots we could discuss. I want to start off with a couple projects that are currently ongoing for you, maybe that you're knee-deep in. If you could just start us off with a couple research projects that you have going on these days. Seely: Yeah. Sure. One of the ones that you mentioned, the integrative oncology study, is a big study that we're doing. That's probably the most interesting and complex study that we're running right now. I say running a little bit loosely because we actually haven't started it yet. We're waiting on final ethics approval. We're nearing the runway anyways. This is the Thoracic POISE Trial, which is the Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial. The goal for this trial is to explore the impact of naturopathic medicine in addition to conventional usual care at the hospital for patients who have thoracic cancers and are eligible for surgery. What we're doing in this study is we're going to be randomizing a group of these patients into receiving standard usual care at the hospital only, or getting usual care plus an integrated approach delivered by a naturopathic doctor prior to their surgery and for a year after the surgery as well. We have a whole battery of different outcomes that we're exploring, including adverse events related to surgery. We're looking at quality of life measures. We're looking at some biological surrogates, including immune function, inflammatory changes in the body, and we're looking at some cost-effective outcomes and, ultimately, long-term survival and recurrence rate over 5 years. This study is a long study. It's going to take us probably, by the end of the whole thing, maybe 12 years. We're starting off with a feasibility component to explore the interventions and how effective they can be applied before we move into the randomized component with a much larger population. Kaczor: That brings up a question in my mind. That is, when you talk about the feasibility aspect, are you designing it such that the intervention will be standardized across the patients, or will this be more naturopathic in it being more personalized per patient in a systems-based approach? Seely: Yeah. That's a great question. We've struggled a lot with how to develop the intervention in a way that could be representative of naturopathic medicine in the field. Then, also scalable and standardizable in a way that it could be replicated in another trial. I think we balanced it as much as we can from both ends. It depends on who you speak to I suppose around that. The goal is truly holistic or a whole-person care. We have components that relate to the use of targeted natural health products that we've standardized for this population. We've got a nutritional approach that we've standardized to some degree. We have interventions related to improving fitness and pulmonary fitness in particular. Then we have interventions related to mind and body medicine and psychological well-being. Those four domains comprise the types of interventions that we have. Within each of those, we developed specific interventions that we detailed how this would be applied, and under what conditions, to these patients so that this can be clearly documented. There is a standardized approach that we're using. There is some flexibility in terms of the patients and how they represent in terms of making changes to the intervention. For example, if someone presents with diarrhea, they will be provided with probiotics as well as their core interventions. If they have weight loss, they would get whey protein as well. If they're experiencing mucositis or neuropathy, we'll apply glutamine. There are some things that we can tweak based on symptoms that the patient has. Initially, at least, everyone in the study is going to get a course of intervention that everyone will receive similar. We don't know what is going to be providing what effect. That's the nature of a pragmatic study like this. We'll be able to say, at the end of the day, that this whole-person approach, what effect does it have on the outcomes that we're looking at. These are important outcomes for these patients regardless. It's a bit of a black box at the end of the day. We won't be able to identify what specific intervention has what effect, but we can say, as a whole, naturopathic medicine in this setting can make a difference in outcomes related to survival or adverse events related to surgery. Things like duration of hospitalization after surgery, so we'll have information on that. Kaczor: This particular trial is being done in conjunction with area cancer centers and your center specifically. This is site-specific. Is that right? Seely: It is initially. The feasibility study, which won't be randomized, is going to happen with the Ottawa Hospital as the hospital site. Then, the Ottawa Integrative Cancer Center (OICC) will be the site where the naturopathic care will be delivered. Once we have run in a few of them, when we do the randomization, we do plan on having at least 2 additional sites across the country. We have a couple places identified that will be good sources for recruitment. It will take place in other sites as well. Kaczor: Great. I like the idea of it being a whole-systems approach because that's one of the things that we run into in naturopathic medicine is that the reductionist view of a single agent being studied is never reflective of what we're actually doing. That's great. My understanding is you have another study that has multiple locations. Is that correct? Seely: Yeah. We're doing another study, which is quite different. It's an observational study called CUSIOS. It's the Canadian/US Integrative Oncology Study. This is being done in partnership with Bastyr University and the other co-PI is Dr. Leanna Standish. Really, we're looking at in this study over a 6- to 7-year period to recruit and observe the interventions that are given to patients with late-stage cancer, 4 types of late-stage cancer. We're looking at what the naturopathic care interventions are being given to these patients at 11 different clinics across North America—5 in Canada and 6 in the United States. Each of these clinics are being led by what one would consider to be a naturopathic oncologist or someone steeped in naturopathic oncology. We're tying to look at clinics that have some of the best therapies, the most innovative and useful therapies, in the naturopathic oncology realm being given to these patients. We want to look at what those interventions are and we're documenting that using REDCap. Then, we're going to be also following these patients to see what the survival rate is amongst these patients. Then, we're also doing a substudy within that looking at cost and quality of life. Their experience through the care as well in a more of a qualitative kind of a way. Again, a lot of outcomes that we're trying to track, it is observational so it won't have the same sort of subjective biases for sure. It'll give us, I think, a lot of really good information about what the practice of naturopathic oncology is ostensively at its best, and what are some of the outcomes that we're seeing patients go through these advanced integrative oncology clinics. Kaczor: Yeah. Let me ask you this as far as time horizons. These are both pretty lengthy studies. I have a 2-part question. One, when can we look forward to preliminary results or the first publications coming out of either of these trials? Two, are they registered such that, regardless of how the data shakes out, positive or negative, that it will be published? I understand that once trials are registered in a certain way, the data has to be published at some point. Seely: Yes. For sure, we will publish regardless of what the outcomes are. The CUSIOS study is ongoing. It is registered under clinicaltrials.gov. Thoracic POISE is not yet registered because we haven't got it through ethics yet. We will be establishing that soon. We will be publishing those, no question. We actually have submitted one publication so far and it's been peer reviewed. This is looking at the intervention development process that we used for thoracic POISE, which is really a collaborative effort with physicians at the hospitals, at the hospital pharmacists, the naturopathic doctors as well. That's being submitted for publication. We also have information related to the survey. When you survey the whole profession through the Oncology Association of Naturopathic Physicians (OncANP), we wanted to know what were the best interventions, what were people using. That really helped influence the interventions that are being chosen for this study. That's also being submitted for publication. Hopefully, we'll see those out in the literature in the next few months. Kaczor: Great. I'm going to switch gears just a little bit. You mentioned pharmacists and other doctors at these cancer centers. I guess one question to us out there, whether we're clinicians or we're in the research realm, is collaboration and creating those bridges that are required to really study integrative oncology. My question to you is, how to go about that? Maybe just let me know if, over the years, has it changed? It seems like it would be easier now than say 10 years ago, or even 15 years ago. Can you speak on that a little bit? Seely: Yeah. I think it has gotten easier. There's more of an openness to doing the evaluations and the studies. We're seeing more interest in research, I would say overall, into naturopathic and complementary approaches to care. There's still certainly resistance that exists. Academics and researchers are much more open to looking at these questions typically than clinicians may be. The interest is really in trying to figure out what works from a research perspective. I do believe it's getting more easy to collaborate in that way. Funding opportunities are not easy for sure. I think that, within the naturopathic community, we know that we have a lot of low-lying fruit from our own intervention palate that it should be researched. There's good reason for it, and there's a lot of [inaudible], and there's some early evidence of benefit. [inaudible] have not been researched adequately in many cases. In terms of building relationships and trying to engage with others, I found doing graduate work was really helpful. There's an automatic process that you engage with others. There's an expectation to be collaborative, and reaching out to people who are doing research at institutions to say, "You've got a good idea about an intervention that might have some effect." I think people are surprised when there's really a good openness for those questions. I think finding people in academic institutions that have a focus on research is a good place to start and to try to start a dialogue and a relationship really. Kaczor: Yeah. Let me ask you one last question. That is, if people are interested either in your area geographically or they want to look up the centers that are involved in the US/Canadian collaboration trial, where should they look for more information? Seely: Clinicaltrials.gov will list all the different sites that are involved in the trial. I think there's more information related to that probably on our website, OICC.ca. Yeah, clinicaltrials.gov will have the information related to that. Kaczor: Okay. Great. As far as getting funding, this is usually in collaboration. I mean, you have a research background and a masters degree and such, so your advice to clinicians who just have their clinical degree is to collaborate basically and find others who are of the same passion for whatever question is being asked and maybe try for grants in that direction? Is that correct? Seely: Yeah. I think trying to become part of a team, reaching out to different groups that are involved in research techniques through the colleges. They often have research departments and may have some information related to that. Talking to universities and people there. A really great place to start, I think, in terms of doing research too is publishing case reports. There's more of a drive for case reports in [inaudible]. That's something that is ... I know that the AANP is trying to support more case reports. I think that diving into that and writing up a case report that really clinically just gets someone steep into what the evidence is in the literature around the topic and leads to more investment. It's a more accessible entry point into research I would say. Kaczor: That's a great bit of advice. We, as clinicians, are always ... Everybody has a few cases that are extraordinary over the years, so that's a good bit of advice, especially within integrative oncology when extraordinary cases do happen. It would be great to document that and see if there's commonalities and create studies like yours around those treatments. That would be incredible. I really appreciate your work, your time with me today. I hope we get to talk again in the near future. Thanks, Dugald. Seely: Thanks so much, Dr. Kaczor. I totally appreciate the journal and what you're doing with it. Thanks for having me. Kaczor: Take care.
Coming up on Biotechnology Focus Radio : The future of made-in-Canada CAR-T cells looks bright, Roche Canada and Merck each launch their own individual collaborative cancer research initiatives, and using immunotherapies to kill brain cancer Welcome to another episode of Biotechnology Focus Radio. I’m your host Shawn Lawrence, here to give you a rundown of this week’s top stories on the Canadian biotech scene. As you can tell by our teaser intro, cancer research and new initiatives into new therapies to tackle the disease figure prominently in our news headlines this week, and this is not a coincidence as February happens to be National Cancer Prevention Awareness Month. Story 1 On that note, our first story takes us to Ottawa, ON, where a team of researchers at the Children’s Hospital of Eastern Ontario (CHEO) have made a discovery, featured in Nature, center around a promising combination of immunotherapies that are able to deliver a one-two punch to brain cancer tumours in mice. Led by Dr. Robert Korneluk, distinguished professor at the University of Ottawa and senior scientist at the CHEO Research Institute, the Ottawa reseach team was able to show in mice that a combination of drugs known as SMAC Mimetics and immune checkpoint inhibitors (ICIs) amplifies kill rates of cancer tumour cells in laboratory testing. The research team also discovered a new mechanism by which the combination promotes long-term immunity against glioblastoma tumours. The combination therapy also proved to be highly effective against breast cancer and multiple myeloma. According to Dr. Korneluk, these findings represent a significant evolution in the field of immunotherapy, for the first time showing the synergistic tumour-killing impact of combining SMAC Mimetics with immune checkpoint inhibitors for glioblastoma. As part of this latest project SMAC Mimetics known as LCL161 and Birinapant were combined with ICI antibodies targeting PD-1 and CTLA-4 immune checkpoints. The findings have their roots in research conducted back in 2014, when a team of scientists led by Dr. Korneluk discovered that combining SMAC Mimetics with immune stimulators or live virus therapies had a synergistic or amplified tumour-killing effect that was greater than either agent on its own. Today’s news shows that SMAC Mimetics also have a powerful synergistic effect with ICIs, relatively new drugs that are showing great promise in the clinic. Eric Lacasse, a scientist at the CHEO Research Institute, adds that two drug companies have initiated human clinical trials this year to assess the impact of this combination of SMAC Mimetics and ICIs on patients with a variety of cancers. Although it could be years before any clinical trials begin for adults or children with the deadly brain cancer, glioblastoma, we’re looking forward to seeing how scientific evidence from these experimental treatments adds to our knowledge. It’s an exciting, exploratory field and we hope we’ve hit a home run.” Shawn Beug was the lead author of both the 2014 and 2017 papers, and the research was funded by the Canadian Cancer Society Research Institute, Brain Canada (with financial support from Health Canada through the Canada Brain Research Fund) and the Canadian Institutes of Health Research. In addition, the work was supported by donations to the Ottawa Regional Cancer Foundation, the Kiwanis Medical Foundation and the CHEO Foundation. Story 2 Continuing with the Cancer Research theme, Hoffmann-La Roche Limited (Roche Canada) reports that Toronto’s Princess Margaret Cancer Centre has joined the company's global cancer immunotherapy Centres of Research Excellence (imCORE) Network. The network brings together the world's leading scientific and clinical experts in cancer immunotherapy to collaborate on the investigation and development of promising new treatment approaches for the disease. As part of gaining a better understanding immune biology and cancer, and to ultimately improve treatment options, this includes initiating pre-clinical and clinical research based on the latest scientific discoveries in cancer immunotherapy and to aggregate, as well as share data within the Network to help accelerate research for people living with cancer. The imCORE Network is comprised of 21 academic centres, inclusive of Princess Margaret Cancer Centre, from nine countries across the globe. Dr. Lillian Siu, medical oncologist at Princess Margaret Cancer Centre and Site Lead for the imCORE Network explains why the imCORE newtwork is exciting in the follow audio clip. http://stream1.newswire.ca/media/2017/02/14/20170214_C8704_VIDEO_EN_881863.mp4 As a part of a global announcement regarding the launch of the imCORE Network, Roche has also made a commitment to invest up to 100 million Swiss Francs (more than $130 million Canadian dollars) to support basic and clinical research collaborations related to cancer immunotherapy. Story 3 In an exciting public/private partnership, stakeholders in Quebec have launched a new research, development and investment hub to help accelerate the fight against cancer. The hub, called Oncopole is backed by a $15-million investment by Merck that will be administered over three years and overseen by the Fonds de recherche du Québec – Santé (FRQS). Through its model, Oncopole brings together various stakeholders under one flagship hub in oncology. It’s conception was structured with the involvement of more than 50 experts from the scientific community over the past year, who helped to identify its priorities. Recognizing the range of resources and infrastructures currently available as well as the strategic positioning of many researchers in Québec, the Hub will aspire to strengthen the research and innovation ecosystem in the province. Some functions of Oncopole will include enabling the incubation and creation of companies that will capitalize on innovation; and positioning cancer care in Québec among the best in the world in terms of clinical outcome, patient experience and system efficiency. Based on a thorough analysis of the various hosting possibilities identified across Québec, the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal was selected as the establishment which will host the Oncopole’s coordinating offices. Additionally, the FRQS and Merck hope that this initial investment will attract other partners to join the Oncopole and make it a truly collaborative initiative. Story 4 Switching gears to the bioindustrial sector, the Biotechnology Innovation Organization (BIO) announces that registration and housing are now open for the 2017 World Congress on Industrial Biotechnology. The conference, now in its 14th year brings brings together from across the globe business leaders, investors, academics and policymakers in the biofuels, biobased products, renewable chemicals, synthetic biology, food ingredients and biomass sectors. Industrial and environmental biotechnology is at the forefront of the biobased economy, generating good-paying jobs and making cleaner products and processes. This year event will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Canada. According to Brent Erickson, executive vice president, Industrial and Environmental at BIO, two new tracks-Flavors, Fragrances and Food Ingredients and Agricultural Crop Technologies and Biomass Supply-have been added to this year’s programming, representing the extended value chain of industrial biotechnology. He adds that the decision to bring the World Congress back to Montréal had very much to do with the success of past events, and the local industries continues support of what has grown into the world’s largest industrial biotechnology conference. In 2016, the BIO World Congress on Industrial Biotechnology drew around 907 industry leaders from 529 companies, 32 countries and 31 states, as well as the District of Columbia and hosted a record 1,961 partnering meetings. For more information on the conference visit http://www.bio.org/worldcongress. Story 4 In our final story this week, BioCanRx, and its partners, are investing $11 million to support 16 collaborative research projects in novel therapies to cure cancer. including research aimed at developing Canada’s clinical Chimeric Antigen Receptor modified T cell (CAR-T) manufacturing capabilities. Considered a powerful new tool in the fight against cancer, CAR-T is on the cutting edge of cancer therapeutics, showing promise in paediatric and adult patients with certain blood cancers such as acute lymphoblastic leukemia and lymphoma. While promising, the development of such therapies require sophisticated manufacturing and expertise. Canada currently does have the basic laboratory infrastructure in place, and with this funding could take significant steps towards fully developing the expertise and capacity required to deliver this technology. The BioCanRx investment is going to research projects that will advance several innovative engineered T cell designs, to accelerate delivery of these novel concepts into clinical testing in Canada. Dr. John Bell, Scientific Director, BioCanRx adds his CAR-T manufacturing initiative is unique in that it represents the Canadian academic community recognizing a gap and stepping up to drive Canadian solutions to meet grassroots efforts taking place in the U.S., China and Europe. He discusses CAR-T cell manufacturing in Canada in the following audio provided by BioCanRX: https://biocanrx.com/wp-content/uploads/custom%20images/BioCanRx_Dr_JohnBellCART3.mp4 To help ensure CAR-T cell therapy is brought to patients safely and effectively, BioCanRx is funding a companion Clinical, Social, and Economic Impact project. It will review the existing base of knowledge and involve patient consultation to design a rigorous CAR-T clinical trial protocol ready to implement once the products are ready for a phase 1 clinical trial. Dr. Manoj Lalu, associate scientist, assistant professor, Clinical Epidemiology and Regenerative Medicine Programs, Ottawa Hospital Research Institute, The Ottawa Hospital and Department of Anesthesiology and Pain Medicine, University of Ottawa discusses CAR-T therapy clinical trial design in the following audio clip. https://biocanrx.com/wp-content/uploads/custom%20images/Dr.%20Lalu%20-%20BioCanRx.mp4 To access the full list of the 16 projects funded, be sure to visit https://biocanrx.com/project-dashboards. Well that wraps up another episode of the Biotechnology Focus Podcast. We hope you enjoyed it. Be sure to let us know what you think, and we’re also always looking for story ideas and suggestions for future shows, and of course we’d love to hear from you as well, simply reach out to us via twitter @biotechfocus, or by email at the following email address press@promotivemedia.ca. And remember, you can also listen to past episodes online via our podcast portal at www.biotechnologyfocus.ca . For all of us here at Biotechnology Focus, thanks for listening.
Our first story takes us to Southwestern Ontario, where the government of Ontario and Bioindustrial Innovation Canada have partnered to launch a new commercialization hub in Sarnia-Lambton As part of the partnership, the Government of Ontario says it will invest $3 million over four years through the Business Growth Initiative to help build the Centre of Excellence for the Commercialization of Sustainable Chemistry Innovations at the Western Sarnia-Lambton Research Park, Canada’s largest clean-tech incubator. The new centre will focus on bridging critical gaps and addressing commercialization challenges facing the industrial biotechnology and manufacturing sectors, including developing expertise, forging commercial partnerships, and accessing risk-capital to help bring discoveries and technologies from the lab to the marketplace. The good news goes further as its expected that 400 high-value jobs will be created at the new site. The region is known for its Biomanufacturing prowess, turning sustainable feedstock — renewable resources such as agricultural and forestry by-products and wastes — into energy, value-added chemicals and materials for use in a variety of everyday products such as plastics, personal care products, automotive parts and food additives. The use of plant-derived chemicals and bio-manufacturing processes can significantly reduce greenhouse gas emissions when compared to conventional petroleum based production methods. One example of a successful company in this space is BioAmber, a sustainable chemical company in Sarnia that produces plant-derived succinic acid and is able to achieve a 100 per cent reduction in GHGs over conventional methods. Similarly, EcoSynthetix, a Burlington-based renewable chemicals company produces paper coatings while cutting GHG emissions by 63 per cent compared to the norm. The funding for the new centre was previously announced as part of this year’s provincial budget. In regulatory news coming out of Quebec, the Government there, through its Ministry of Health has denied Theratechnologies bid to have EGRIFTA®, an injectable prescription medicine to reduce the excess abdominal fat in HIV-infected patients with lipodystrophy, added to a list of reimbursed medications. Company CEO and president Luc Tanguay called the decision by the province, which also happens to be the province where EGRIFTA® was discovered, regretful. “The government is sending a message that supporting research is not a priority,” he said via a release adding that it is quite paradoxical that, after supporting the development of EGRIFTA® through tax credits, the Quebec government will not accept to reimburse it.” The decision, made by the Quebec Minister of Health, Gaétan Barrette, was based on a recommendation by the Institut National d’Excellence en Santé et Services Sociaux(INESSS). Theratechnologies submitted to INESSS a comprehensive dossier which included data that led to public and private reimbursement by a large number of governmental agencies and insurers in Canada and in the United States. INESSS concluded that the decrease of visceral adipose tissue in HIV patients does not constitute a therapeutic advantage. Nevertheless, INESSS did recognize the efficacy EGRIFTA® and the quality of its clinical studies. In response, Theratechnologies did say that despite the decision, they will continue to work with the Ministry and INESSS, and that they will submit to INESSS, within the prescribed timelines, a request for a revision of their decision. In Cancer Research News, the Movember Foundation, the Ontario Institute for Cancer Research (OICR) and Prostate Cancer Canada are providing $3 million in funding for a new Phase 3 clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The trial, called PRECISE, will be led by Dr. Laurence Klotz of the Sunnybrook Research Institute in Toronto, a world leader in the field of prostate cancer research and in the global adoption of active surveillance, a standard practice to monitor patients with low risk prostate cancer. The primary objective of the multi-centre trial is to determine whether MRI imaging can spare some men from undergoing a biopsy and avoid the possible associated side effects. Dr. Klotz discusses the PRECISE TRIAL in the following audio... Data management and analysis for the trial will be conducted by the Ontario Clinical Oncology Group (OCOG) in the Escarpment Cancer Research Institute, a Hamilton Health Sciences and McMaster University institute. Earlier this month, five contenders of the third AmorChem KNOCK OUT™ competition climbed into the ring at a special Lumira-AmorChem hosted event to duke it out against a panel of Heavyweight Champions, or judges for a chance to win a coveted $500,000 financing from AmorChem. All the contenders displayed remarkable courage and agility in the ring, yet only one could stand victorious. In the end, Dr. Anne-Marie Mes-Masson, CRCHUM scientific director at the Institut du cancer de Montréal, for her project focused on the development of small molecule inhibitors of the Ran GTPase, was named the champion. The panel of “champion” judges included: Richard Lesniewski, a pharmaceutical industry veteran formerly from Abbott (AbbVie), GlaxoSmithKline and Madison Vaccines; John Gillard, science entrepreneur formerly from Merck Canada, BioChem Pharma and Aegera Therapeutics; John Bell, scientist-entrepreneur from the Ottawa Hospital Research Institute and the University of Ottawa; and Lloyd Segal, best known as a serial biotech entrepreneur and investor at Persistence Capital Partners and Trimera Capital. Christopher Hall, a renowned radio and newspaper columnist and comedian, was the master of ceremony. Both Elizabeth Douvile and Ines Holzbaur,, general partners at AmorChem which we’ve highlighted in past podacast shows called the competition a success, achieving its goal of increasing the Quebec and Canadian research communities’ awareness of AmorChem and in reaching out to researchers who may not have been aware of the possibility of commercializing aspects of their work. Among the other competitors were: Dr. John Coles, University of Toronto & Dr. Jason Maynes, The Hospital for Sick Children and University of Toronto; Dr. Julie Forman Kay, The Hospital for Sick Children and University of Toronto & Dr. Nahum Sonenberg, McGill University; Dr. Réjean Lapointe, Université de Montréal and CRCHUM & Dr. Sophie Lerouge, École de technologie supérieure and CRCHUM; and Dr. Moutih Rafei, Université de Montréal. The Lumira-AmorChem conference also highlighted the respective roles of the two venture capital groups in the financing of the life sciences sector, and included presentations from Lumira Capital portfolio companies and from AmorChem’s first spin-off company, Mperia. Our final stories this week come out of Ottawa where the Government of Canada had two announcements related to supporting Canada’s science community. The first saw Kirsty Duncan, Minister of Science, launch an independent review of federal funding for fundamental science, to assess the program machinery that is currently in place to support science and scientists in Canada. The scope of the review includes the three granting councils along with certain federally funded organizations such as the Canada Foundation for Innovation. The review will be led by an independent panel of distinguished research leaders and innovators including Dr. David Naylor, former president of the University of Toronto and chair of the panel. Other panelists include: Dr. Robert Birgeneau, former chancellor, University of California, Berkeley, Dr. Martha Crago, Vice-President, Research, Dalhousie University, Mike Lazaridis, co-founder, Quantum Valley Investments, Dr. Claudia Malacrida, Associate Vice-President, Research, University of Lethbridge, Dr. Art McDonald, former director of the Sudbury Neutrino Laboratory, Nobel Laureate, Dr. Martha Piper, interim president, University of British Columbia, Dr. Rémi Quirion, Chief Scientist, Quebec, Dr. Anne Wilson, Canadian Institute for Advanced Research Successful Societies Fellow and professor of psychology, Wilfrid Laurier University The panel will spend the next six months seeking input from the research community and Canadians on how to optimize support for fundamental science in Canada. The panel will also survey international best practices for funding science and examine whether emerging researchers face barriers that prevent them from achieving career goals. In addition to collecting input from the research community, the panel will also invite Canadians to participate in the review through an online consultation. In further Canadian Science Policy news Navdeep Bains, Minister of Innovation, Science and Economic Development, has put forward a new Innovation Agenda . Jointly with Minister of Science Kirsty Duncan, and, Minister of Small Business and Tourism Bardish Chagger, the initiative or Agenda will aim at building an inclusive and innovative Canada focused on six areas for action: including promoting an entrepreneurial and creative society, supporting global science excellence, building world-leading clusters and partnerships, growing companies and accelerating clean growth, competing in a digital world and improving ease of doing business. These six action areas, which form the Innovation Agenda, will be the focus of a summer-longperiod of public engagement that will result in an action plan. Central to this plan will be a call to action to all sectors of society. Minister Bains invited all Canadians to share their ideas on the Agenda, and should watch for the launch of an interactive website that will allow them to offer their suggestions on positioning Canada as a global leader in innovation. In addition, round-table discussions will take place across the country. That wraps up this weeks show, be sure to You can find us online at www.biotechnologyfocus.ca and follow us on twitter @BiotechFocus check out our latest issue on our website!
Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a post-doctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, Department of Medicine, in 1989. He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a Senior Scientist with the Ottawa Hospital Research Institute and Professor of Medicine at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. He is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and is a fellow of the Royal Society of Canada.
In this interview, Dugald Seely, ND, founder and executive director of the Ottawa Integrative Cancer Centre, describes the research projects presently underway at the center. He also describes the pragmatic research design that is presently helping to advance the field of integrative research and he discusses the future of integrative cancer research. Approximate listening time: 16 minutes About the Expert Dugald Seely ND, MSc, FABNO, leads the clinical practice and cancer research program for theOttowa Integrative Cancer Centre (OICC). In addition to his clinical role as a naturopathic doctor he also serves as the director of research & clinical epidemiology at the Canadian College of Naturopathic Medicine, affiliate investigator for the Ottawa Hospital Research Institute, and board member for the Society for Integrative Oncology. Seely completed his Master of Science in cancer research at the University of Toronto and is a Fellow of the American Board of Naturopathic Oncology (FABNO). As a clinician scientist, Dugald has been awarded competitive grant and trainee funding from CIHR, CBCRA, the SickKids Foundation, the Lotte and John Hecht Memorial Foundation, the Ottawa Regional Cancer Foundation, and the Gateway for Cancer Research Foundation.
An examination of clinical data from one Canadian diagnostic centre shows that active surveillance has become an increasingly common management strategy for men with low-grade prostate cancer, instead of immediate treatment. Dr. Rodney Breau, co-author of the research article, explains in this interview podcast. Dr. Breau is a surgical oncologist at The Ottawa Hospital, assistant professor of urology at The University of Ottawa, and associate scientist at the Ottawa Hospital Research Institute. Full article (open access): www.cmaj.ca/lookup/doi/10.1503/cmaj.150832
RCTs of treatment as prevention have shown significant prevention of onward HIV transmission among serodiscordant couples, but observational studies of clinical practice have not consistently replicated these findings. There are particular concerns among men who have sex with men (MSM). In this podcast, Dr. Paul MacPherson explores some of the issues. Dr. MacPherson is a specialist in the Division of Infectious Diseases at the Ottawa Hospital, an associate professor in the Department of Medicine, and the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa, and a clinician scientist at the Ottawa Hospital Research Institute. In their analysis article, Dr. MacPherson and his co-author Patrick O’Byrne examine HIV treatment as prevention in MSM. Full article (subscription required): www.cmaj.ca/lookup/doi/10.1503/cmaj.150605
© 2020-2025 Ivy Podcast Discovery LLC
